{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " # Multi-Step Agentic RAG with Azure AI Services\n",
    " \n",
    " This notebook demonstrates a Multi-Step Agentic RAG (Retrieval Augmented Generation) system that provides a cardiology-focused AI assistant with access to multiple data sources:\n",
    "\n",
    " 1. **Structured Data** (Azure SQL Database) - Patient medical records and information\n",
    " 2. **Unstructured Data** (Azure AI Search) - Medical guidelines from the American College of Cardiology\n",
    " 3. **Web Data** (Azure AI Agent Service with Bing Grounding Tool) - Real-time web information\n",
    " \n",
    " The system uses Azure OpenAI's function/tool calling capabilities to orchestrate the retrieval process and generate comprehensive responses to medical queries."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "#!pip install -r requirements.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Import Libraries and Set Up Environment\n",
    " We'll start by importing the necessary libraries and loading environment variables.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "import pandas as pd\n",
    "import asyncio  # noqa: F401\n",
    "import aiohttp  # noqa: F401\n",
    "import pyodbc  # noqa: F401\n",
    "import sqlalchemy\n",
    "from azure.ai.projects import AIProjectClient\n",
    "from azure.ai.agents.models import BingGroundingTool\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import DefaultAzureCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "from dotenv import load_dotenv\n",
    "from openai import AzureOpenAI\n",
    "from rich.console import Console\n",
    "from rich.panel import Panel\n",
    "\n",
    "load_dotenv()\n",
    "console = Console()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Configure Azure Services\n",
    "\n",
    "Next, we set up all the necessary configurations for the Azure services we'll be using.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-01-01-preview\n"
     ]
    }
   ],
   "source": [
    "# Azure OpenAI configuration\n",
    "AZURE_OPENAI_API_KEY = os.getenv(\"AZURE_OPENAI_API_KEY\")\n",
    "AZURE_OPENAI_API_VERSION = os.getenv(\"AZURE_OPENAI_API_VERSION\")\n",
    "AZURE_OPENAI_ENDPOINT = os.getenv(\"AZURE_OPENAI_ENDPOINT\")\n",
    "AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME = os.getenv(\"AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME\")\n",
    "\n",
    "print(AZURE_OPENAI_API_VERSION)\n",
    "\n",
    "# Azure AI Search configuration\n",
    "AZURE_SEARCH_ENDPOINT = os.getenv(\"AZURE_SEARCH_SERVICE_ENDPOINT\", \"https://your-search-service.search.windows.net\")\n",
    "AZURE_SEARCH_KEY = os.getenv(\"AZURE_SEARCH_ADMIN_KEY\", \"your-azure-search-key\")\n",
    "SEARCH_INDEX_NAME = \"acc-guidelines-index\"\n",
    "\n",
    "# Azure AI Project configuration for Bing Grounding\n",
    "AZURE_FOUNDRY_ENDPOINT = os.getenv(\"AZURE_FOUNDRY_ENDPOINT\", \"your-azure-connection-string\")\n",
    "BING_CONNECTION_NAME = os.getenv(\"BING_CONNECTION_NAME\", \"fsunavalabinggrounding\")\n",
    "\n",
    "# Azure SQL connection details (for patient data)\n",
    "server = os.getenv(\"AZURE_SQL_SERVER_NAME\")\n",
    "database = os.getenv(\"AZURE_SQL_DATABASE_NAME\")\n",
    "username = os.getenv(\"AZURE_SQL_USER_NAME\")\n",
    "password = os.getenv(\"AZURE_SQL_PASSWORD\")\n",
    "driver = '{ODBC Driver 17 for SQL Server}'\n",
    "\n",
    "# Create an Azure SQL connection string\n",
    "AZURE_SQL_CONNECTION_STRING = f\"DRIVER={driver};SERVER={server};DATABASE={database};UID={username};PWD={password}\"\n",
    "\n",
    "# Initialize the Azure OpenAI client\n",
    "openai_client = AzureOpenAI(\n",
    "    api_key=AZURE_OPENAI_API_KEY,\n",
    "    api_version=AZURE_OPENAI_API_VERSION,\n",
    "    azure_endpoint=AZURE_OPENAI_ENDPOINT  # type: ignore\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Define Tool Functions\n",
    "\n",
    "Now we'll implement the three tool functions that our agent will use to access different data sources.\n",
    "\n",
    "### 3.1 Unstructured Data Tool: ACC Guidelines Search via Azure AI Search\n",
    "\n",
    "This tool retrieves relevant American College of Cardiology guidelines using Azure AI Search with semantic and vector search capabilities.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_acc_guidelines(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the Azure AI Search index 'acc-guidelines-index' \n",
    "    for relevant American College of Cardiology (ACC) guidelines.\n",
    "    \"\"\"\n",
    "    credential = AzureKeyCredential(AZURE_SEARCH_KEY)\n",
    "    client = SearchClient(\n",
    "        endpoint=AZURE_SEARCH_ENDPOINT,\n",
    "        index_name=SEARCH_INDEX_NAME,\n",
    "        credential=credential,\n",
    "    )\n",
    "    \n",
    "    results = client.search(\n",
    "        search_text=query,\n",
    "        vector_queries=[\n",
    "            VectorizableTextQuery(\n",
    "                text=query,\n",
    "                k_nearest_neighbors=10,   # Adjust as needed\n",
    "                fields=\"embedding\"   # Adjust based on your index schema\n",
    "            )\n",
    "        ],\n",
    "        query_type=\"semantic\",\n",
    "        semantic_configuration_name=\"default\",\n",
    "        search_fields=[\"chunk\"],\n",
    "        top=10,\n",
    "        include_total_count=True\n",
    "    )\n",
    "    \n",
    "    retrieved_texts = []\n",
    "    for result in results:\n",
    "        content_chunk = result.get(\"chunk\", \"\")\n",
    "        retrieved_texts.append(content_chunk)\n",
    "    \n",
    "    context_str = \"\\n\".join(retrieved_texts) if retrieved_texts else \"No relevant guidelines found.\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: ACC Guidelines Search\\nQuery: {query}\",\n",
    "            style=\"bold yellow\"\n",
    "        )\n",
    "    )\n",
    "    return context_str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ### 3.2 Web Data Tool: Bing Web Grounding via Azure AI Agent Service\n",
    " \n",
    " This tool uses the Azure AI Agent Service with the Bing Web Grounding Tool to search for real-time information from the web. This is a significant improvement over direct Bing Search API calls, as it leverages Azure's AI Agent framework for better context and grounding and remains compliant with Bing's Terms of Use."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_bing_grounding(query: str):\n",
    "    \"\"\"\n",
    "    Uses the Azure AI Projects client to perform a Bing search with grounding.\n",
    "\n",
    "    Args:\n",
    "        query (str): The search query\n",
    "\n",
    "    Returns:\n",
    "        str: The search results\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Create or get a project client\n",
    "        project_client = AIProjectClient.from_connection_string(\n",
    "            credential=DefaultAzureCredential(),\n",
    "            conn_str=AZURE_FOUNDRY_ENDPOINT,\n",
    "        )\n",
    "\n",
    "        # Set up the Bing grounding tool\n",
    "        bing_connection = project_client.connections.get(\n",
    "            connection_name=BING_CONNECTION_NAME\n",
    "        )\n",
    "        conn_id = bing_connection.id\n",
    "        bing = BingGroundingTool(connection_id=conn_id)\n",
    "\n",
    "        # Create a temporary agent with the Bing tool\n",
    "        with project_client:\n",
    "            agent = project_client.agents.create_agent(\n",
    "                model=\"gpt-4o\",\n",
    "                name=\"temp-bing-agent\",\n",
    "                instructions=\"Perform a search and return the results directly without additional commentary\",\n",
    "                tools=bing.definitions,\n",
    "                headers={\"x-ms-enable-preview\": \"true\"},\n",
    "            )\n",
    "\n",
    "            # Create thread and message\n",
    "            thread = project_client.agents.create_thread()\n",
    "            message = project_client.agents.create_message(\n",
    "                thread_id=thread.id,\n",
    "                role=\"user\",\n",
    "                content=query,\n",
    "            )\n",
    "\n",
    "            # Run the agent\n",
    "            run = project_client.agents.create_and_process_run(\n",
    "                thread_id=thread.id, assistant_id=agent.id\n",
    "            )\n",
    "\n",
    "            # Get the results\n",
    "            if run.status == \"completed\":\n",
    "                # Get the assistant's response\n",
    "                messages = project_client.agents.list_messages(thread_id=thread.id)\n",
    "\n",
    "                # Extract the actual message text from the response\n",
    "                for msg in reversed(\n",
    "                    messages.data\n",
    "                ):  # Use .data to access the list of messages\n",
    "                    if msg.role == \"assistant\" and msg.content:\n",
    "                        # Extract the text value from the content\n",
    "                        for content_item in msg.content:\n",
    "                            if content_item.type == \"text\":\n",
    "                                return content_item.text.value  # Return the actual text\n",
    "\n",
    "                return \"No specific weather information found.\"\n",
    "\n",
    "            # Clean up\n",
    "            project_client.agents.delete_agent(agent.id)\n",
    "\n",
    "            # If we couldn't get a response\n",
    "            if run.status == \"failed\":\n",
    "                return f\"Search failed: {run.last_error}\"\n",
    "\n",
    "            return \"No results found.\"\n",
    "\n",
    "    except Exception as e:\n",
    "        return f\"Error performing Bing search: {str(e)}\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.3 Structured Data Tool: Patient Data Query via Azure SQL\n",
    "\n",
    "This tool queries a SQL database containing patient medical data, transforming natural language questions into SQL queries.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def lookup_patient_data(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Queries the 'PatientMedicalData' table in Azure SQL and returns the results as a string.\n",
    "    'query' should be a valid SQL statement.\n",
    "    This version uses SQLAlchemy to create an engine, which is fully supported by pandas.read_sql.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Construct the connection URI for SQLAlchemy\n",
    "        connection_uri = (\n",
    "            f\"mssql+pyodbc://{username}:{password}@{server}/{database}\"\n",
    "            \"?driver=ODBC+Driver+17+for+SQL+Server\"\n",
    "        )\n",
    "        engine = sqlalchemy.create_engine(connection_uri)\n",
    "        \n",
    "        # Use the engine in pandas.read_sql, which avoids the warning\n",
    "        df = pd.read_sql(query, engine)\n",
    "        if df.empty:\n",
    "            return \"No rows found.\"\n",
    "        return df.to_string(index=False)\n",
    "    except Exception as e:\n",
    "        return f\"Database error: {str(e)}\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ## 4. Define Tools for OpenAI Function Calling\n",
    " Now we'll configure these tools to work with OpenAI's function calling feature, which allows the LLM to dynamically select and use these tools during conversation.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "tools = [\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_acc_guidelines\",\n",
    "            \"description\": \"Query the ACC guidelines for official cardiology recommendations. Use keywords related to cardiology conditions, treatments, or guidelines.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Keywords or specific question related to cardiology guidelines.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_bing_grounding\",\n",
    "            \"description\": \"Perform a public web search for real-time or external information using Bing Grounding. For example, 'FDA new hyperlipidemia drugs', 'recent hypertension medication approvals'.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"General query to retrieve public data.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"lookup_patient_data\",\n",
    "            \"description\": (\n",
    "                \"Query Azure SQL PatientMedicalData table. Schema: \"\n",
    "                \"PatientID: INT (PK, Identity), FirstName: VARCHAR(100), LastName: VARCHAR(100), \"\n",
    "                \"DateOfBirth: DATE, Gender: VARCHAR(20), ContactNumber: VARCHAR(100), EmailAddress: VARCHAR(100), \"\n",
    "                \"Address: VARCHAR(255), City: VARCHAR(100), PostalCode: VARCHAR(20), Country: VARCHAR(100), \"\n",
    "                \"MedicalCondition: VARCHAR(255), Medications: VARCHAR(255), Allergies: VARCHAR(255), BloodType: VARCHAR(10), \"\n",
    "                \"LastVisitDate: DATE, SmokingStatus: VARCHAR(50), AlcoholConsumption: VARCHAR(50), ExerciseFrequency: VARCHAR(50), \"\n",
    "                \"Occupation: VARCHAR(100), Height_cm: DECIMAL(5,2), Weight_kg: DECIMAL(5,2), BloodPressure: VARCHAR(20), \"\n",
    "                \"HeartRate_bpm: INT, Temperature_C: DECIMAL(3,1), Notes: VARCHAR(MAX). Use SQL to retrieve patient data.\"\n",
    "            ),\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Valid SQL query for PatientMedicalData table to get patient information.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "]\n",
    "\n",
    "# Map the tool names to the actual function implementations\n",
    "tool_implementations = {\n",
    "    \"search_acc_guidelines\": search_acc_guidelines,\n",
    "    \"search_bing_grounding\": search_bing_grounding,\n",
    "    \"lookup_patient_data\": lookup_patient_data,\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 5. Define System Prompt for the Agent\n",
    "\n",
    "The system prompt sets the context and instructions for the Agent, defining its role and capabilities.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------------------\n",
    "# System Prompt for the Agent\n",
    "# ----------------------------\n",
    "SYSTEM_PROMPT = (\n",
    "    \"You are a cardiology-focused AI assistant with access to three tools:\\n\"\n",
    "    \"1) 'lookup_patient_data' for querying patient records from Azure SQL.\\n\"\n",
    "    \"2) 'search_acc_guidelines' for official ACC guidelines.\\n\"\n",
    "    \"3) 'search_bing_grounding' for real-time public information.\\n\\n\"\n",
    "    \"You can call these tools in any order, multiple times if needed, to gather all the context.\\n\"\n",
    "    \"Stop calling tools only when you have enough information to provide a final, cohesive answer.\\n\"\n",
    "    \"Then output your final answer to the user.\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 6. Implement the Multi-Step Agent\n",
    "\n",
    " Now we'll create the agent that orchestrates the entire process. This agent will:\n",
    "\n",
    "1.  Receive a user query\n",
    "2.  Decide which tools to call and in what order\n",
    "3.  Parse the results from each tool\n",
    "4.  Synthesize a comprehensive answer\n",
    "\n",
    "The agent can make multiple calls to different tools before providing a final answer, allowing for complex, multi-step reasoning.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_multi_step_agent(user_query: str, max_steps: int = 3):\n",
    "    \"\"\"\n",
    "    A multi-step agent that orchestrates tool selection and execution.\n",
    "    \"\"\"\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": SYSTEM_PROMPT},\n",
    "        {\"role\": \"user\", \"content\": user_query}\n",
    "    ]\n",
    "\n",
    "    for step in range(max_steps):\n",
    "        console.print(Panel(f\"**Step {step+1}**: Starting step {step+1}\", title=\"Step Start\", style=\"bold cyan\"))\n",
    "        \n",
    "        try:\n",
    "            # Log current message state for debugging\n",
    "            console.print(Panel(f\"Messages before API call:\\n{json.dumps(messages, indent=2)}\", title=\"Current Messages\", style=\"dim\"))\n",
    "            \n",
    "            # Make API call to OpenAI\n",
    "            response = openai_client.chat.completions.create(\n",
    "                model=AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME,\n",
    "                messages=messages, # type: ignore\n",
    "                tools=tools, # type: ignore\n",
    "                tool_choice=\"auto\",\n",
    "                max_tokens=8000,\n",
    "            )\n",
    "            response_message = response.choices[0].message\n",
    "            \n",
    "            # Debug the raw response\n",
    "            console.print(Panel(f\"Raw response message:\\n{response_message}\", title=\"Raw Response\", style=\"dim\"))\n",
    "            \n",
    "            # Check if the response contains tool calls\n",
    "            if response_message.tool_calls:\n",
    "                # Create a properly structured assistant message with tool_calls\n",
    "                messages.append({\n",
    "                    \"role\": \"assistant\",\n",
    "                    \"content\": response_message.content,  # This might be None when tool_calls are present\n",
    "                    \"tool_calls\": [\n",
    "                        {\n",
    "                            \"id\": tool_call.id,\n",
    "                            \"type\": \"function\",\n",
    "                            \"function\": {\n",
    "                                \"name\": tool_call.function.name,\n",
    "                                \"arguments\": tool_call.function.arguments\n",
    "                            }\n",
    "                        } for tool_call in response_message.tool_calls\n",
    "                    ] # type: ignore\n",
    "                })\n",
    "                \n",
    "                # Now handle each tool call separately\n",
    "                for tool_call in response_message.tool_calls:\n",
    "                    function_name = tool_call.function.name\n",
    "                    tool_call_id = tool_call.id  # Extract the exact tool_call_id\n",
    "                    arguments_str = tool_call.function.arguments\n",
    "                    \n",
    "                    try:\n",
    "                        function_args = json.loads(arguments_str) if arguments_str.strip() else {}\n",
    "                    except json.JSONDecodeError:\n",
    "                        function_args = {}\n",
    "                        console.print(Panel(\"Warning: Could not decode tool call arguments\", title=\"JSONDecodeError\", style=\"bold red\"))\n",
    "                    \n",
    "                    # Ensure the 'query' key is present\n",
    "                    if \"query\" not in function_args or not function_args[\"query\"]:\n",
    "                        function_args[\"query\"] = user_query\n",
    "                    \n",
    "                    console.print(Panel(\n",
    "                        f\"**Step {step+1}**: LLM calls tool [bold]{function_name}[/bold]\\n\\n\"\n",
    "                        f\"**Arguments**:\\n{json.dumps(function_args, indent=2)}\",\n",
    "                        title=\"Tool Call\",\n",
    "                        style=\"bold blue\"\n",
    "                    ))\n",
    "                    \n",
    "                    # Call the appropriate tool function\n",
    "                    tool_fn = tool_implementations.get(function_name)\n",
    "                    if tool_fn is None:\n",
    "                        tool_output = f\"[Error] No implementation for tool '{function_name}'.\"\n",
    "                    else:\n",
    "                        tool_output = tool_fn(**function_args)\n",
    "                    \n",
    "                    # Add the tool response with EXACTLY the same tool_call_id \n",
    "                    messages.append({\n",
    "                        \"role\": \"tool\",\n",
    "                        \"tool_call_id\": tool_call_id,  # CRITICAL: Use exactly the same ID\n",
    "                        \"name\": function_name,\n",
    "                        \"content\": str(tool_output)\n",
    "                    })\n",
    "                    \n",
    "                    console.print(Panel(f\"Tool output added to messages:\\n{str(tool_output)}\", title=\"Tool Response Added\", style=\"green\"))\n",
    "            else:\n",
    "                # No tool calls, just add the assistant's message and return the final answer\n",
    "                messages.append({\n",
    "                    \"role\": \"assistant\",\n",
    "                    \"content\": response_message.content # type: ignore\n",
    "                })\n",
    "                \n",
    "                # Display the final answer\n",
    "                final_answer = response_message.content\n",
    "                console.print(Panel(final_answer, title=\"Final Answer\", style=\"bold green\", border_style=\"yellow\")) # type: ignore\n",
    "                return  # Successfully received final answer\n",
    "        \n",
    "        except Exception as e:\n",
    "            console.print(Panel(f\"Error during step {step+1}: {str(e)}\", title=\"Error\", style=\"bold red\"))\n",
    "            # Print the current message structure to help with debugging\n",
    "            console.print(Panel(f\"Current message structure:\\n{json.dumps(messages, indent=2)}\", title=\"Message Structure at Error\", style=\"red\"))\n",
    "            raise  # Re-raise the exception for further debugging\n",
    "\n",
    "    # If we reach the maximum steps without a final answer, show a warning\n",
    "    console.print(Panel(\"Max steps reached without a final answer. Stopping.\", title=\"Warning\", style=\"bold red\"))\n",
    "    return"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ## 7. Execute the Agent with a Sample Query\n",
    " \n",
    " Now let's run the agent with a cardiology-related question to see how it works. The agent will decide which tools to use and in what order to provide the most comprehensive answer."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_yVXBesnr1g0Ttb2OmZkWUH5z',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"first-line therapy for hypertension in elderly patients\"}',              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ name='search_acc_guidelines'), type='function')], annotations=[])                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_yVXBesnr1g0Ttb2OmZkWUH5z', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"first-line therapy for hypertension in elderly patients\"}', \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mname='search_acc_guidelines'), type='function')], annotations=[])\u001b[0m\u001b[2m                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"first-line therapy for hypertension in elderly patients\"                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"first-line therapy for hypertension in elderly patients\"\u001b[0m\u001b[1;34m                                           \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800000; text-decoration-color: #800000; font-weight: bold\">╭─────────────────────────────────────────────────────</span> Error <span style=\"color: #800000; text-decoration-color: #800000; font-weight: bold\">─────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000; font-weight: bold\">│ Error during step 1: () The given API key doesn't match service's internal, primary or secondary keys.          │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000; font-weight: bold\">│ Code:                                                                                                           │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000; font-weight: bold\">│ Message: The given API key doesn't match service's internal, primary or secondary keys.                         │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;31m╭─\u001b[0m\u001b[1;31m────────────────────────────────────────────────────\u001b[0m Error \u001b[1;31m────────────────────────────────────────────────────\u001b[0m\u001b[1;31m─╮\u001b[0m\n",
       "\u001b[1;31m│\u001b[0m\u001b[1;31m \u001b[0m\u001b[1;31mError during step 1: () The given API key doesn't match service's internal, primary or secondary keys.\u001b[0m\u001b[1;31m         \u001b[0m\u001b[1;31m \u001b[0m\u001b[1;31m│\u001b[0m\n",
       "\u001b[1;31m│\u001b[0m\u001b[1;31m \u001b[0m\u001b[1;31mCode: \u001b[0m\u001b[1;31m                                                                                                         \u001b[0m\u001b[1;31m \u001b[0m\u001b[1;31m│\u001b[0m\n",
       "\u001b[1;31m│\u001b[0m\u001b[1;31m \u001b[0m\u001b[1;31mMessage: The given API key doesn't match service's internal, primary or secondary keys.\u001b[0m\u001b[1;31m                        \u001b[0m\u001b[1;31m \u001b[0m\u001b[1;31m│\u001b[0m\n",
       "\u001b[1;31m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800000; text-decoration-color: #800000\">╭──────────────────────────────────────────</span> Message Structure at Error <span style=\"color: #800000; text-decoration-color: #800000\">───────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ Current message structure:                                                                                      │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"        │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│         \"id\": \"call_yVXBesnr1g0Ttb2OmZkWUH5z\",                                                                  │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│           \"name\": \"search_acc_guidelines\",                                                                      │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│           \"arguments\": \"{\\\"query\\\":\\\"first-line therapy for hypertension in elderly patients\\\"}\"                │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #800000; text-decoration-color: #800000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[31m╭─\u001b[0m\u001b[31m─────────────────────────────────────────\u001b[0m Message Structure at Error \u001b[31m──────────────────────────────────────────\u001b[0m\u001b[31m─╮\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31mCurrent message structure:\u001b[0m\u001b[31m                                                                                     \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m[\u001b[0m\u001b[31m                                                                                                              \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m  {\u001b[0m\u001b[31m                                                                                                            \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"role\": \"system\",\u001b[0m\u001b[31m                                                                                          \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[31m     \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[31m  \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[31m      \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[31m                                 \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m  },\u001b[0m\u001b[31m                                                                                                           \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m  {\u001b[0m\u001b[31m                                                                                                            \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"role\": \"user\",\u001b[0m\u001b[31m                                                                                            \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"content\": \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\u001b[0m\u001b[31m       \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m  },\u001b[0m\u001b[31m                                                                                                           \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m  {\u001b[0m\u001b[31m                                                                                                            \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"role\": \"assistant\",\u001b[0m\u001b[31m                                                                                       \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"content\": null,\u001b[0m\u001b[31m                                                                                           \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    \"tool_calls\": [\u001b[0m\u001b[31m                                                                                            \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m      {\u001b[0m\u001b[31m                                                                                                        \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m        \"id\": \"call_yVXBesnr1g0Ttb2OmZkWUH5z\",\u001b[0m\u001b[31m                                                                 \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m        \"type\": \"function\",\u001b[0m\u001b[31m                                                                                    \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m        \"function\": {\u001b[0m\u001b[31m                                                                                          \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m          \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[31m                                                                     \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m          \"arguments\": \"{\\\"query\\\":\\\"first-line therapy for hypertension in elderly patients\\\"}\"\u001b[0m\u001b[31m               \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m        }\u001b[0m\u001b[31m                                                                                                      \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m      }\u001b[0m\u001b[31m                                                                                                        \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m    ]\u001b[0m\u001b[31m                                                                                                          \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m  }\u001b[0m\u001b[31m                                                                                                            \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m│\u001b[0m\u001b[31m \u001b[0m\u001b[31m]\u001b[0m\u001b[31m                                                                                                              \u001b[0m\u001b[31m \u001b[0m\u001b[31m│\u001b[0m\n",
       "\u001b[31m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "ename": "HttpResponseError",
     "evalue": "() The given API key doesn't match service's internal, primary or secondary keys.\nCode: \nMessage: The given API key doesn't match service's internal, primary or secondary keys.",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mHttpResponseError\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[12], line 2\u001b[0m\n\u001b[0;32m      1\u001b[0m user_question_1 \u001b[38;5;241m=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mWhat does the ACC recommend as first-line therapy for hypertension in elderly patients?\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m----> 2\u001b[0m \u001b[43mrun_multi_step_agent\u001b[49m\u001b[43m(\u001b[49m\u001b[43muser_question_1\u001b[49m\u001b[43m)\u001b[49m\n",
      "Cell \u001b[1;32mIn[11], line 76\u001b[0m, in \u001b[0;36mrun_multi_step_agent\u001b[1;34m(user_query, max_steps)\u001b[0m\n\u001b[0;32m     74\u001b[0m     tool_output \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m[Error] No implementation for tool \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mfunction_name\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[0;32m     75\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m---> 76\u001b[0m     tool_output \u001b[38;5;241m=\u001b[39m \u001b[43mtool_fn\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mfunction_args\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     78\u001b[0m \u001b[38;5;66;03m# Add the tool response with EXACTLY the same tool_call_id \u001b[39;00m\n\u001b[0;32m     79\u001b[0m messages\u001b[38;5;241m.\u001b[39mappend({\n\u001b[0;32m     80\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mrole\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtool\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m     81\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtool_call_id\u001b[39m\u001b[38;5;124m\"\u001b[39m: tool_call_id,  \u001b[38;5;66;03m# CRITICAL: Use exactly the same ID\u001b[39;00m\n\u001b[0;32m     82\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mname\u001b[39m\u001b[38;5;124m\"\u001b[39m: function_name,\n\u001b[0;32m     83\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcontent\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;28mstr\u001b[39m(tool_output)\n\u001b[0;32m     84\u001b[0m })\n",
      "Cell \u001b[1;32mIn[6], line 30\u001b[0m, in \u001b[0;36msearch_acc_guidelines\u001b[1;34m(query)\u001b[0m\n\u001b[0;32m     13\u001b[0m results \u001b[38;5;241m=\u001b[39m client\u001b[38;5;241m.\u001b[39msearch(\n\u001b[0;32m     14\u001b[0m     search_text\u001b[38;5;241m=\u001b[39mquery,\n\u001b[0;32m     15\u001b[0m     vector_queries\u001b[38;5;241m=\u001b[39m[\n\u001b[1;32m   (...)\u001b[0m\n\u001b[0;32m     26\u001b[0m     include_total_count\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m     27\u001b[0m )\n\u001b[0;32m     29\u001b[0m retrieved_texts \u001b[38;5;241m=\u001b[39m []\n\u001b[1;32m---> 30\u001b[0m \u001b[43m\u001b[49m\u001b[38;5;28;43;01mfor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mresult\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01min\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mresults\u001b[49m\u001b[43m:\u001b[49m\n\u001b[0;32m     31\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcontent_chunk\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m \u001b[49m\u001b[43mresult\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mchunk\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[0;32m     32\u001b[0m \u001b[43m    \u001b[49m\u001b[43mretrieved_texts\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mappend\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcontent_chunk\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mc:\\Users\\jhoni\\.conda\\envs\\agentic-rag-venv\\Lib\\site-packages\\azure\\search\\documents\\_paging.py:57\u001b[0m, in \u001b[0;36mSearchItemPaged.__next__\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m     55\u001b[0m     first_iterator \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_first_iterator_instance()\n\u001b[0;32m     56\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_page_iterator \u001b[38;5;241m=\u001b[39m itertools\u001b[38;5;241m.\u001b[39mchain\u001b[38;5;241m.\u001b[39mfrom_iterable(first_iterator)\n\u001b[1;32m---> 57\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mnext\u001b[39;49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_page_iterator\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[1;32mc:\\Users\\jhoni\\.conda\\envs\\agentic-rag-venv\\Lib\\site-packages\\azure\\core\\paging.py:75\u001b[0m, in \u001b[0;36mPageIterator.__next__\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m     73\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mStopIteration\u001b[39;00m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mEnd of paging\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m     74\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m---> 75\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_get_next\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcontinuation_token\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     76\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m AzureError \u001b[38;5;28;01mas\u001b[39;00m error:\n\u001b[0;32m     77\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m error\u001b[38;5;241m.\u001b[39mcontinuation_token:\n",
      "File \u001b[1;32mc:\\Users\\jhoni\\.conda\\envs\\agentic-rag-venv\\Lib\\site-packages\\azure\\search\\documents\\_paging.py:138\u001b[0m, in \u001b[0;36mSearchPageIterator._get_next_cb\u001b[1;34m(self, continuation_token)\u001b[0m\n\u001b[0;32m    136\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21m_get_next_cb\u001b[39m(\u001b[38;5;28mself\u001b[39m, continuation_token):\n\u001b[0;32m    137\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m continuation_token \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m--> 138\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mdocuments\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msearch_post\u001b[49m\u001b[43m(\u001b[49m\u001b[43msearch_request\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_initial_query\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_kwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    140\u001b[0m     _next_link, next_page_request \u001b[38;5;241m=\u001b[39m unpack_continuation_token(continuation_token)\n\u001b[0;32m    142\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_client\u001b[38;5;241m.\u001b[39mdocuments\u001b[38;5;241m.\u001b[39msearch_post(search_request\u001b[38;5;241m=\u001b[39mnext_page_request, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_kwargs)\n",
      "File \u001b[1;32mc:\\Users\\jhoni\\.conda\\envs\\agentic-rag-venv\\Lib\\site-packages\\azure\\core\\tracing\\decorator.py:105\u001b[0m, in \u001b[0;36mdistributed_trace.<locals>.decorator.<locals>.wrapper_use_tracer\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    103\u001b[0m span_impl_type \u001b[38;5;241m=\u001b[39m settings\u001b[38;5;241m.\u001b[39mtracing_implementation()\n\u001b[0;32m    104\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m span_impl_type \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m--> 105\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m    107\u001b[0m \u001b[38;5;66;03m# Merge span is parameter is set, but only if no explicit parent are passed\u001b[39;00m\n\u001b[0;32m    108\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m merge_span \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m passed_in_parent:\n",
      "File \u001b[1;32mc:\\Users\\jhoni\\.conda\\envs\\agentic-rag-venv\\Lib\\site-packages\\azure\\search\\documents\\_generated\\operations\\_documents_operations.py:784\u001b[0m, in \u001b[0;36mDocumentsOperations.search_post\u001b[1;34m(self, search_request, request_options, **kwargs)\u001b[0m\n\u001b[0;32m    782\u001b[0m     map_error(status_code\u001b[38;5;241m=\u001b[39mresponse\u001b[38;5;241m.\u001b[39mstatus_code, response\u001b[38;5;241m=\u001b[39mresponse, error_map\u001b[38;5;241m=\u001b[39merror_map)\n\u001b[0;32m    783\u001b[0m     error \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_deserialize\u001b[38;5;241m.\u001b[39mfailsafe_deserialize(_models\u001b[38;5;241m.\u001b[39mErrorResponse, pipeline_response)\n\u001b[1;32m--> 784\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m HttpResponseError(response\u001b[38;5;241m=\u001b[39mresponse, model\u001b[38;5;241m=\u001b[39merror)\n\u001b[0;32m    786\u001b[0m deserialized \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_deserialize(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mSearchDocumentsResult\u001b[39m\u001b[38;5;124m\"\u001b[39m, pipeline_response\u001b[38;5;241m.\u001b[39mhttp_response)\n\u001b[0;32m    788\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mcls\u001b[39m:\n",
      "\u001b[1;31mHttpResponseError\u001b[0m: () The given API key doesn't match service's internal, primary or secondary keys.\nCode: \nMessage: The given API key doesn't match service's internal, primary or secondary keys."
     ]
    }
   ],
   "source": [
    "user_question_1 = \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\n",
    "run_multi_step_agent(user_question_1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular diseases?\"                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular diseases?\"\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_iAOtTON8Nhk8hU6KIbIQOeoz',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"latest FDA approvals Ozempic cardiovascular disease\"}',                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ name='search_bing_grounding'), type='function'),                                                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_3jzH1RKe67FlErM2jzL3LJ3h', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"Ozempic clinical trials cardiovascular outcomes\"}', name='search_bing_grounding'), type='function')])          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_iAOtTON8Nhk8hU6KIbIQOeoz', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"latest FDA approvals Ozempic cardiovascular disease\"}', \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mname='search_bing_grounding'), type='function'), \u001b[0m\u001b[2m                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_3jzH1RKe67FlErM2jzL3LJ3h', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"Ozempic clinical trials cardiovascular outcomes\"}', name='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"latest FDA approvals Ozempic cardiovascular disease\"                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"latest FDA approvals Ozempic cardiovascular disease\"\u001b[0m\u001b[1;34m                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the only GLP-1      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ receptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (CKD)【0†source】【2†source】. This approval is based on the results from the FLOW phase 3b kidney outcomes     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ trial which demonstrated a statistically significant reduction in risks associated with these                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions【2†source】.                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mOn January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the only GLP-1 \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreceptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(CKD)【0†source】【2†source】. This approval is based on the results from the FLOW phase 3b kidney outcomes \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtrial which demonstrated a statistically significant reduction in risks associated with these \u001b[0m\u001b[32m                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions【2†source】.\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"Ozempic clinical trials cardiovascular outcomes\"                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"Ozempic clinical trials cardiovascular outcomes\"\u001b[0m\u001b[1;34m                                                   \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in patients with    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ type 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the risk of major     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial infarction, and │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly driven by fewer       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ non-fatal myocardial infarctions and strokes【7†source】.                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in patients with \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mtype 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the risk of major \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial infarction, and\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly driven by fewer \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mnon-fatal myocardial infarctions and strokes【7†source】.\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular diseases?\"                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_bing_grounding\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"latest FDA approvals Ozempic cardiovascular disease\\\"}\"                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       },                                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_bing_grounding\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"Ozempic clinical trials cardiovascular outcomes\\\"}\"                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_bing_grounding\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ only GLP-1 receptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ disease (CKD)\\u30100\\u2020source\\u3011\\u30102\\u2020source\\u3011. This approval is based on the results from the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ FLOW phase 3b kidney outcomes trial which demonstrated a statistically significant reduction in risks           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ associated with these conditions\\u30102\\u2020source\\u3011.\"                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_bing_grounding\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with type 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk of major adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ infarction, and non-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ driven by fewer non-fatal myocardial infarctions and strokes\\u30107\\u2020source\\u3011.\"                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular diseases?\"\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"latest FDA approvals Ozempic cardiovascular disease\\\"}\"\u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      },\u001b[0m\u001b[2m                                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"Ozempic clinical trials cardiovascular outcomes\\\"}\"\u001b[0m\u001b[2m                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_iAOtTON8Nhk8hU6KIbIQOeoz\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"On January 28, 2025, the FDA approved a new indication for Ozempic (semaglutide), making it the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2monly GLP-1 receptor agonist approved to reduce the risk of kidney disease worsening, kidney failure (end-stage \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mkidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdisease (CKD)\\u30100\\u2020source\\u3011\\u30102\\u2020source\\u3011. This approval is based on the results from the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFLOW phase 3b kidney outcomes trial which demonstrated a statistically significant reduction in risks \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2massociated with these conditions\\u30102\\u2020source\\u3011.\"\u001b[0m\u001b[2m                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_3jzH1RKe67FlErM2jzL3LJ3h\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic (semaglutide) in \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with type 2 diabetes and high cardiovascular risk. The trial showed a significant reduction in the \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk of major adverse cardiovascular events (MACE), which includes cardiovascular death, non-fatal myocardial \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minfarction, and non-fatal stroke, with a 26% risk reduction compared to placebo. The reduction was mainly \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdriven by fewer non-fatal myocardial infarctions and strokes\\u30107\\u2020source\\u3011.\"\u001b[0m\u001b[2m                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content='Ozempic (semaglutide) has seen significant advancements in its FDA approval and  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ clinical trial outcomes related to cardiovascular diseases:\\n\\n1. **FDA Approval**: On January 28, 2025, the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ FDA granted a new indication for Ozempic, making it the only GLP-1 receptor agonist approved specifically to    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD). This approval was based │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ on the findings from the FLOW phase 3b kidney outcomes trial, which demonstrated a significant reduction in the │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risks associated with these conditions.\\n\\n2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular outcomes of Ozempic in patients with type 2 diabetes who are at high cardiovascular risk. The    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ results revealed a 26% reduction in the risk of major adverse cardiovascular events (MACE)—which includes       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke—when compared to a placebo. The     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk reduction was primarily attributed to fewer occurrences of non-fatal myocardial infarctions and strokes in │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the Ozempic group.\\n\\nThese findings suggest that Ozempic not only aids in glycemic control but also has        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ protective benefits against cardiovascular events in diabetic patients at risk.', refusal=None,                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ role='assistant', audio=None, function_call=None, tool_calls=None)                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content='Ozempic (semaglutide) has seen significant advancements in its FDA approval and \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclinical trial outcomes related to cardiovascular diseases:\\n\\n1. **FDA Approval**: On January 28, 2025, the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFDA granted a new indication for Ozempic, making it the only GLP-1 receptor agonist approved specifically to \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD). This approval was based\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mon the findings from the FLOW phase 3b kidney outcomes trial, which demonstrated a significant reduction in the\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisks associated with these conditions.\\n\\n2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular outcomes of Ozempic in patients with type 2 diabetes who are at high cardiovascular risk. The \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mresults revealed a 26% reduction in the risk of major adverse cardiovascular events (MACE)—which includes \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular death, non-fatal myocardial infarction, and non-fatal stroke—when compared to a placebo. The \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk reduction was primarily attributed to fewer occurrences of non-fatal myocardial infarctions and strokes in\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe Ozempic group.\\n\\nThese findings suggest that Ozempic not only aids in glycemic control but also has \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprotective benefits against cardiovascular events in diabetic patients at risk.', refusal=None, \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrole='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Ozempic (semaglutide) has seen significant advancements in its FDA approval and clinical trial outcomes related </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> to cardiovascular diseases:                                                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **FDA Approval**: On January 28, 2025, the FDA granted a new indication for Ozempic, making it the only      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> GLP-1 receptor agonist approved specifically to reduce the risk of kidney disease worsening, kidney failure     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> kidney disease (CKD). This approval was based on the findings from the FLOW phase 3b kidney outcomes trial,     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> which demonstrated a significant reduction in the risks associated with these conditions.                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic in        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> patients with type 2 diabetes who are at high cardiovascular risk. The results revealed a 26% reduction in the  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> risk of major adverse cardiovascular events (MACE)—which includes cardiovascular death, non-fatal myocardial    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> infarction, and non-fatal stroke—when compared to a placebo. The risk reduction was primarily attributed to     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> fewer occurrences of non-fatal myocardial infarctions and strokes in the Ozempic group.                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> These findings suggest that Ozempic not only aids in glycemic control but also has protective benefits against  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> cardiovascular events in diabetic patients at risk.                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mOzempic (semaglutide) has seen significant advancements in its FDA approval and clinical trial outcomes related\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mto cardiovascular diseases:\u001b[0m\u001b[1;32m                                                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **FDA Approval**: On January 28, 2025, the FDA granted a new indication for Ozempic, making it the only \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mGLP-1 receptor agonist approved specifically to reduce the risk of kidney disease worsening, kidney failure \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m(end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mkidney disease (CKD). This approval was based on the findings from the FLOW phase 3b kidney outcomes trial, \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mwhich demonstrated a significant reduction in the risks associated with these conditions.\u001b[0m\u001b[1;32m                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Clinical Trials**: The SUSTAIN 6 clinical trial evaluated the cardiovascular outcomes of Ozempic in \u001b[0m\u001b[1;32m      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mpatients with type 2 diabetes who are at high cardiovascular risk. The results revealed a 26% reduction in the \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mrisk of major adverse cardiovascular events (MACE)—which includes cardiovascular death, non-fatal myocardial \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32minfarction, and non-fatal stroke—when compared to a placebo. The risk reduction was primarily attributed to \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mfewer occurrences of non-fatal myocardial infarctions and strokes in the Ozempic group.\u001b[0m\u001b[1;32m                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThese findings suggest that Ozempic not only aids in glycemic control but also has protective benefits against \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mcardiovascular events in diabetic patients at risk.\u001b[0m\u001b[1;32m                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_2 = \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts cardiovascular diseases?\"\n",
    "run_multi_step_agent(user_question_2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"\u001b[0m\u001b[2m                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_Oh3Ab9yhY2Q36sTIaJ5PWaAm',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\":\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'), type='function')])    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_Oh3Ab9yhY2Q36sTIaJ5PWaAm', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\":\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\'%Hypertension%\\' AND Medications LIKE \\'%Lisinopril%\\'\"}', name='lookup_patient_data'), type='function')])\u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ Medications LIKE '%Lisinopril%'\"                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE '%Hypertension%' AND \u001b[0m\u001b[1;34m          \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34mMedications LIKE '%Lisinopril%'\"\u001b[0m\u001b[1;34m                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1071                                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m    \u001b[0m\u001b[32m                                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1071\u001b[0m\u001b[32m                                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"lookup_patient_data\",                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\":\\\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ '%Hypertension%' AND Medications LIKE '%Lisinopril%'\\\"}\"                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"lookup_patient_data\",                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"    \\n1071\"                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"How many patients have Hypertension and are prescribed Lisinopril?\"\u001b[0m\u001b[2m                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\":\\\"SELECT COUNT(*) FROM PatientMedicalData WHERE MedicalCondition LIKE \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'%Hypertension%' AND Medications LIKE '%Lisinopril%'\\\"}\"\u001b[0m\u001b[2m                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_Oh3Ab9yhY2Q36sTIaJ5PWaAm\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"    \\n1071\"\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content='There are 1,071 patients who have Hypertension and are prescribed Lisinopril.',  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)                                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content='There are 1,071 patients who have Hypertension and are prescribed Lisinopril.', \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrefusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> There are 1,071 patients who have Hypertension and are prescribed Lisinopril.                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mThere are 1,071 patients who have Hypertension and are prescribed Lisinopril.\u001b[0m\u001b[1;32m                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "user_question_3 = \"How many patients have Hypertension and are prescribed Lisinopril?\"\n",
    "# The agent should generate a valid SQL query, for example:\n",
    "## Note, the answer will depend on the actual data in the database (it should return 1071!)\n",
    "run_multi_step_agent(user_question_3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myou confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthere are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"\u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None,             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tool_calls=[ChatCompletionMessageToolCall(id='call_wDYynvTCJlXDSeGHihDW3rof',                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName=\\'Gloria\\' AND         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName=\\'Paul\\'\"}', name='lookup_patient_data'), type='function'),                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_AcZAtI7rblAPdmxzoC6nxGgg', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"hyperlipidemia\"}', name='search_acc_guidelines'), type='function'),                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_Wj83hyOr277uKGy1oSceoOi9', function=Function(arguments='{\"query\": \"FDA   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ new hyperlipidemia drugs February 2025\"}', name='search_bing_grounding'), type='function')])                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=None, refusal=None, role='assistant', audio=None, function_call=None, \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtool_calls=[ChatCompletionMessageToolCall(id='call_wDYynvTCJlXDSeGHihDW3rof', \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName=\\'Gloria\\' AND \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName=\\'Paul\\'\"}', name='lookup_patient_data'), type='function'), \u001b[0m\u001b[2m                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_AcZAtI7rblAPdmxzoC6nxGgg', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"hyperlipidemia\"}', name='search_acc_guidelines'), type='function'), \u001b[0m\u001b[2m                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_Wj83hyOr277uKGy1oSceoOi9', function=Function(arguments='{\"query\": \"FDA \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnew hyperlipidemia drugs February 2025\"}', name='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND LastName='Paul'\"\u001b[0m\u001b[1;34m                     \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Notes                                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│          1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Cove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ year parent. Happen energy level anyone position. Few available thought world development.                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNotes\u001b[0m\u001b[32m                                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[32m              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32myear parent. Happen energy level anyone position. Few available thought world development.\u001b[0m\u001b[32m                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"hyperlipidemia\"                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"hyperlipidemia\"\u001b[0m\u001b[1;34m                                                                                    \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: hyperlipidemia                                                                                           │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: hyperlipidemia\u001b[0m\u001b[1;33m                                                                                          \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ received service or treatment for the specific condition. Detailed information on the identification of chronic │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions is available from the CMS Chronic Conditions Data Warehouse (13).                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Table 1                                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Table 1 shows the 10 most common comorbidities for each index cardiovascular condition for beneficiaries ‡65    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index cardiovascular conditions     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 with atrial fibrillation,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and 1,145,719 with stroke. Two conditions that are major cardiovascular risk factors—hypertension and           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hyperlipidemia—constitute the most frequent dyad. Hypertension, hyperlipidemia, and ischemic heart disease were │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the 3 most prevalent comorbidities for patients with heart failure, atrial fibrillation, and stroke, whereas    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension, hyperlipidemia, and diabetes mellitus were the most prevalent comorbidities in those with         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ischemic heart disease; however, arthritis, anemia, chronic obstructive pulmonary disease, and Alzheimer’s      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease also appeared.                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Table 2                                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Table 2 lists the top 5 most prevalent dyad and triad comorbidities for beneficiaries ‡65 years of age with at  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ least 2 (for dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pressure, and ischemic heart disease were most frequently represented in the dyads and triads, with diabetes    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mellitus and arthritis completing the remaining prevalent combinations (14).                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ than in former smokers, and there was a significant relationship between the severity of carotid stenosis and   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pack-years of exposure to tobacco (239). The RRs of finding 60% carotid stenosis were 1.5 and 3.9 among         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin Cerebral Ischemia Databank)         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ studies, respectively (258).                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CLASS I                                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ atherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Evidence: B)                                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ CLASS IIa                                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259).  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (Level of Evidence: B)                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ achieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ among those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (261–264). (Level of Evidence: B)                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reasonable (261,263,265). (Level of Evidence: B)                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI,  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Trial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol,       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ exceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ involving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (267). In the ARIC study, the relationships between lipid values and incident ischemic.                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 73, N O . 2 4 , 2 0 1 9                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Grundy et al. e313                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ As discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4.2.).                                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ However, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4).         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Secondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ addressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ genetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ to age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ A smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ present. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ suggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ starting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ to improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ identified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ have been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ individuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ One approach to identifying young adults who could benefit from statins or drug combination would be to detect  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ significant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ been suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendations for Children and Adolescents                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lifestyle therapy, including moderate caloric restriction and regular aerobic physical activity                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.3-1—S4.4.4.3-4).|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C (S4.4.4.3-1—S4.4.4.3-3,                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ children as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ one-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ rates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ patients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2. Lipid-Lowering Drugs                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Among lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ interventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors.        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Triglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ support their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ summarized in Table S3 in the Web Supplement.                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2.1. Statin Therapy                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ The intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ low-intensity (S3.2.1-1). High-intensity statin therapy typically lowers LDL-C levels by ≥50%,                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ moderate-intensity statin therapy by 30% to 49%, and low-intensity statin therapy by &lt;30% (Table 3). Of course, │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ greater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (Table S4 in the Web Supplement). Statin safety has been extensively evaluated (S3.2.1-19). Statin-associated   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ side effects are discussed in Section 5. Common medications that may potentially interact with statins are      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ listed in Table S5 in the Web Supplement. More information on statin drug–drug interactions can be obtained     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ from the ACC LDL-C Manager (S3.2.1-20).                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2.2. Nonstatin Therapies                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Ezetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants reduce LDL-C levels by 15% to 30%        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ depending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, but they │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ are associated with gastrointestinal complaints (e.g., constipation) and can cause severe hypertriglyceridemia  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ when fasting triglycerides are ≥300 mg/dL (≥3.4 mmol/L). PCSK9 inhibitors are powerful LDL-lowering drugs.      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # O C T O B E R 2 8 , 2 0 1 4 : 1 8 5 1 – 6                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # AHA/ACC/HHS Strategies on Comorbidities                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # T A B L E 1 The 10 Most Common Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Beneficiaries $65 Years of Age (13)                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N =       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1,145,719)|                                                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|---|                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|                                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Hyperlipidemia|2 (69.1)|3 (62.6)|2 (64.4)|2 (69.9)|                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Arthritis|4 (40.6)|6 (45.6)|6 (41.7)|5 (44.2)|                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |HF|6 (36.3)|Index|4 (50.9)|7 (37.2)|                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Chronic kidney disease|7 (30.2)|7 (44.8)|8 (34.4)|8 (35.2)|                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Cataract|8 (21.6)|†|10 (22.6)|†|                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COPD|9 (21.0)|8 (30.9)|9 (23.8)|†|                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |AF|10 (18.7)|9 (28.8)|Index|†|                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Alzheimer’s disease/dementia|†|10 (26.3)|†|9 (33.8)|                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Depression|†|†|†|10 (29.7)|                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Stroke|†|†|†|Index|                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Data shown as rank and percentage of persons with index condition who also had a comorbidity. The percentage   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ is included parenthetically when applicable. †Comorbidity was not in the top 10 for this index condition (13).  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ AF indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # IMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Two general, but important, points emerge from the CMS data. First, a beneficiary with cardiovascular disease   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ but without at least 1 comorbid chronic condition is the exception rather than the rule. Second, whereas common │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ risk factors such as hypertension and hyperlipidemia are associated with the index cardiovascular conditions,   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the index conditions are associated with a constellation of comorbidities, the pathophysiology of which may be  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ distinct from the index condition and for which prevalence increases with age or other factors.                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Organizations that develop CPGs must now consider comorbidities during the development process for              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ disease-specific CPGs. For high-prevalence index conditions, few CPGs address comorbidities (15), and even      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ fewer provide guidance for patients with specific combinations of diseases. Managing patients with multiple     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions is more complex than managing patients with a single disease, and the presence of multiple           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ conditions increases challenges for healthcare providers and patients. Comorbidities may constitute barriers to │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ adherence to CPGs, and caring for patients with multiple comorbidities can affect patient safety if             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ recommendations for diagnosis and treatment in one CPG conflict with those for another condition (16). The      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ complexity of various regimens for multiple comorbidities adds to the difficulty in patient management and      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ assessment of clinical outcomes (17). Furthermore, limited attention has been given to the physical, cognitive, │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ social, psychological, and financial implications of managing comorbidities. Involving patients in the CPG      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ development process, which the AHA/ACC recently initiated, is critically important to fully appreciate patient  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ perspectives (18,19).                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Currently, there are important challenges in addressing common comorbidities in the development and             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ implementation                                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 73, N O . 24, 2019                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Grundy et al. e315                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 25, 2019: e 285 - 350                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # T A B L E 9 Normal and Abnormal Lipid Values in Childhood*                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ | |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|                                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |TC|&amp;lt;170 (&amp;lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Triglycerides (0-9 y)|&amp;lt;75 (&amp;lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Triglycerides (10-19 y)|&amp;lt;90 (&amp;lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |HDL-C|&amp;gt;45 (&amp;gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&amp;lt;40 (&amp;lt;1.0 mmol/L)|                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |LDL-C|&amp;lt;110 (&amp;lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Non–HDL-C|&amp;lt;120 (&amp;lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 38.6; for triglycerides, divide by 88.6.                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Children. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ for LDL-C.                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ †The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles,              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP,         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ National Cholesterol Education Program; SI, Système international d’unités (International System of Units); and │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ TC, total cholesterol.                                                                                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Hypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13).          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.3-13—S4.4.4.3-16).                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ history of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ related genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).                          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Subclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ beginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ considered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ suggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ severe hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ screening), according to studies outside the United States demonstrating efficacy of this approach              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S4.4.4.3-37). Screening for severe                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 7 , N O . 4 , 2 0 2 1                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ capacity or an abnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ limited value and does not show additive value for predicting clinical outcome when baseline measures of        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hemodynamic severity and functional status are considered. In addition, recording hemodynamics with exercise is │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ challenging, and simpler parameters are adequate in most patients (2–4,6–11).                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ As reported in several prospective and retrospective studies, the risk of exercise testing is low in            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ asymptomatic patients with AS. However, exercise testing is avoided in symptomatic patients with AS because of  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ a high risk of complications, including syncope, ventricular tachycardia, and death. In a prospective survey of │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 20 medical centers in Sweden that included 50,000 exercise tests done over an 18-month period, the complication │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ rate was 18.4 per 10,000 tests; morbidity rate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests. │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Although the number of patients with AS was not reported, 12 of the 92 complications occurred in patients with  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ AS: 8 had a decline in blood pressure during exercise, 1 had asystole, and 3 had ventricular tachycardia        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (2,4,5,7–10,12).                                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.2.2. Medical Therapy                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendations for Medical Therapy of AS                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Referenced studies that support the recommendations are summarized in Online Data Supplement 5.                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |1|B-NR|In patients at risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C),   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension should be treated according to standard GDMT, started at a low dose, and gradually titrated upward │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ as needed, with appropriate clinical monitoring (1–3).|                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |1|A|In all patients with calcific AS, statin therapy is indicated for primary and secondary prevention of      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ atherosclerosis on the basis of standard risk scores (4–6).|                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |2b|B-NR|In patients who have undergone TAVI, renin–angiotensin system blocker therapy (ACE inhibitor or ARB)   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ may be considered to reduce the long-term risk of all-cause mortality (7,8).|                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |3: No Benefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of hemodynamic progression of AS (4–6).|                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Medical treatment of hypertension and hyperlipidemia according to GDMT is appropriate for patients with AS. ACE │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ inhibitor or ARB treatment may reduce the mortality rate in patients with AS who underwent TAVI.                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Hypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ overload on the LV in combination with valve obstruction. Concern that antihypertensive medications might       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ result in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ small RCTs, likely because AS does not result in “fixed” valve obstruction until late in the disease process.   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study,             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ higher mortality rate (both P&lt;0.01) than those seen in normotensive patients with AS, although no impact on     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mortality was observed.                                                                                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. Concurrent CAD is common in patients with AS, and all patients should be screened and treated for            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of statin therapy for │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mild to moderate AS, although aortic valve event rates...                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # e300 Grundy et al.                                                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ may be indicated.                                                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ been no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ both primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ administered to patients with primary severe hypercholesterolemia.                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ greater in the combined-therapy group, but there was no difference in carotid intima-media thickness between    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ the 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ placebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years,       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ showed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ than that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ indicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ characteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve &lt;50%  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ reduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ mmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ LDL-C lowering (S4.2-9).                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ with or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.          │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 4. PCSK9 inhibitors are promising drugs for treatment of FH                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ prevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6.      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 366:321–9.                                                                                                      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6.       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ activity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Promot. 2018. 890117118784226.                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24.                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes.           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2009;4:205–14.                                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ lifestyle approach. J Clin Lipidol. 2014;8:181–6.                                                               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109–17.                                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 116:1032–40.                                                                                                    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Intervention Study in Children (DISC). Pediatrics. 2001;107:256–64.                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab.                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 2011;96:E1999–2008.                                                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled,    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia. JAMA Pediatr. 2013;167:708–13.                                                            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ modification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122–3.                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ profile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7.                         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Paediatr. 1992;81:682–5.                                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ S4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemic children.                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Grundy et al.                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # Table 3 High-, Moderate-, and Low-Intensity Statin Therapy*                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |High Intensity| | |Moderate Intensity|Low Intensity|                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |---|---|---|---|---|                                                                                           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |LDL-C lowering†|≥50%| |30%–49%|&amp;lt;30%|                                                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ |Statins|Atorvastatin (40 mg‡) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg (20 mg) Rosuvastatin (5 mg)  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 10 mg Simvastatin 20–40 mg§ Pravastatin 40 mg (80 mg) Lovastatin 40 mg (80 mg) Fluvastatin XL 80 mg Fluvastatin │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 40 mg BID Pitavastatin 1–4 mg|Simvastatin 10 mg Pravastatin 10–20 mg Lovastatin 20 mg Fluvastatin 20–40 mg| |   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Percent LDL-C reductions with the primary statin medications used in clinical practice (atorvastatin,           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ rosuvastatin, simvastatin) were estimated using the median reduction in LDL-C from the VOYAGER database         │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S3.2.1-2). Reductions in LDL-C for other statin medications (fluvastatin, lovastatin, pitavastatin,            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ pravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ hypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type indicates specific statins and doses     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ that were evaluated in RCTs (S3.2.1-3, S3.2.1-5—S3.2.1-16), and the Cholesterol Treatment Trialists’ 2010       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ meta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction in major cardiovascular events.              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ *Percent reductions are estimates from data across large populations. Individual responses to statin therapy    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ varied in the RCTs and should be expected to vary in clinical practice (S3.2.1-2).                              │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ †LDL-C lowering that should occur with the dosage listed below each intensity.                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ ‡Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Decrease through Aggressive Lipid Lowering) study (S3.2.1-3).                                                   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ §Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.                     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ BID indicates twice daily; FDA, U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol;  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ RCT, randomized controlled trial; VOYAGER, an individual patient data meta-analysis of statin therapy in        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ at-risk groups: effects of rosuvastatin, atorvastatin, and simvastatin; and XL, extended release.               │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ # 3.1.2. Lifestyle Therapies and Metabolic Syndrome                                                             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Lifestyle therapies are particularly indicated for the metabolic syndrome, which is a cluster of risk factors   │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death (S3.1.2-1, S3.1.2-2).        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Metabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical definition of metabolic  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ syndrome is that proposed by an international consortium of cardiovascular and diabetes organizations           │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ glucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess weight and             │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ particularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ among both adults and children as levels of overweight and obesity have risen. Metabolic                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreceived service or treatment for the specific condition. Detailed information on the identification of chronic\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions is available from the CMS Chronic Conditions Data Warehouse (13).\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Table 1\u001b[0m\u001b[32m                                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for beneficiaries ‡65 \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32myears of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index cardiovascular conditions \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwere 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 with atrial fibrillation, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand 1,145,719 with stroke. Two conditions that are major cardiovascular risk factors—hypertension and \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhyperlipidemia—constitute the most frequent dyad. Hypertension, hyperlipidemia, and ischemic heart disease were\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe 3 most prevalent comorbidities for patients with heart failure, atrial fibrillation, and stroke, whereas \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension, hyperlipidemia, and diabetes mellitus were the most prevalent comorbidities in those with \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mischemic heart disease; however, arthritis, anemia, chronic obstructive pulmonary disease, and Alzheimer’s \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease also appeared.\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Table 2\u001b[0m\u001b[32m                                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTable 2 lists the top 5 most prevalent dyad and triad comorbidities for beneficiaries ‡65 years of age with at \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mleast 2 (for dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpressure, and ischemic heart disease were most frequently represented in the dyads and triads, with diabetes \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmellitus and arthritis completing the remaining prevalent combinations (14).\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthan in former smokers, and there was a significant relationship between the severity of carotid stenosis and \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpack-years of exposure to tobacco (239). The RRs of finding 60% carotid stenosis were 1.5 and 3.9 among \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin Cerebral Ischemia Databank) \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mstudies, respectively (258).\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[32m                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCLASS I\u001b[0m\u001b[32m                                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32matherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mEvidence: B)\u001b[0m\u001b[32m                                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCLASS IIa\u001b[0m\u001b[32m                                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32matherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259). \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(Level of Evidence: B)\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32machieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mamong those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(261–264). (Level of Evidence: B)\u001b[0m\u001b[32m                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreasonable (261,263,265). (Level of Evidence: B)\u001b[0m\u001b[32m                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI, \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTrial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol, \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minvolving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(267). In the ARIC study, the relationships between lipid values and incident ischemic.\u001b[0m\u001b[32m                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Grundy et al. e313\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAs discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4.2.).\u001b[0m\u001b[32m                                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHowever, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSecondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32maddressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgenetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mto age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mA smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpresent. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msuggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\u001b[0m\u001b[32m               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mstarting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mto improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32midentified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhave been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mindividuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mOne approach to identifying young adults who could benefit from statins or drug combination would be to detect \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msignificant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeen suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.\u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendations for Children and Adolescents\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.\u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlifestyle therapy, including moderate caloric restriction and regular aerobic physical activity \u001b[0m\u001b[32m               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.3-1—S4.4.4.3-4).|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C (S4.4.4.3-1—S4.4.4.3-3,\u001b[0m\u001b[32m                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32melevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mobesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mchildren as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mone-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpatients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\u001b[0m\u001b[32m                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2. Lipid-Lowering Drugs\u001b[0m\u001b[32m                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minterventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTriglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msupport their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msummarized in Table S3 in the Web Supplement.\u001b[0m\u001b[32m                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2.1. Statin Therapy\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mThe intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlow-intensity (S3.2.1-1). High-intensity statin therapy typically lowers LDL-C levels by ≥50%, \u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmoderate-intensity statin therapy by 30% to 49%, and low-intensity statin therapy by <30% (Table 3). Of course,\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgreater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(Table S4 in the Web Supplement). Statin safety has been extensively evaluated (S3.2.1-19). Statin-associated \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mside effects are discussed in Section 5. Common medications that may potentially interact with statins are \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlisted in Table S5 in the Web Supplement. More information on statin drug–drug interactions can be obtained \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfrom the ACC LDL-C Manager (S3.2.1-20).\u001b[0m\u001b[32m                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2.2. Nonstatin Therapies\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mEzetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mincidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants reduce LDL-C levels by 15% to 30% \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdepending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, but they\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mare associated with gastrointestinal complaints (e.g., constipation) and can cause severe hypertriglyceridemia \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwhen fasting triglycerides are ≥300 mg/dL (≥3.4 mmol/L). PCSK9 inhibitors are powerful LDL-lowering drugs.\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# O C T O B E R 2 8 , 2 0 1 4 : 1 8 5 1 – 6\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# AHA/ACC/HHS Strategies on Comorbidities\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# T A B L E 1 The 10 Most Common Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBeneficiaries $65 Years of Age (13)\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N = \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1,145,719)|\u001b[0m\u001b[32m                                                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|---|\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|\u001b[0m\u001b[32m                                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Hyperlipidemia|2 (69.1)|3 (62.6)|2 (64.4)|2 (69.9)|\u001b[0m\u001b[32m                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|\u001b[0m\u001b[32m                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Arthritis|4 (40.6)|6 (45.6)|6 (41.7)|5 (44.2)|\u001b[0m\u001b[32m                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|\u001b[0m\u001b[32m                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|HF|6 (36.3)|Index|4 (50.9)|7 (37.2)|\u001b[0m\u001b[32m                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Chronic kidney disease|7 (30.2)|7 (44.8)|8 (34.4)|8 (35.2)|\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Cataract|8 (21.6)|†|10 (22.6)|†|\u001b[0m\u001b[32m                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COPD|9 (21.0)|8 (30.9)|9 (23.8)|†|\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|AF|10 (18.7)|9 (28.8)|Index|†|\u001b[0m\u001b[32m                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Alzheimer’s disease/dementia|†|10 (26.3)|†|9 (33.8)|\u001b[0m\u001b[32m                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Depression|†|†|†|10 (29.7)|\u001b[0m\u001b[32m                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Stroke|†|†|†|Index|\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Data shown as rank and percentage of persons with index condition who also had a comorbidity. The percentage \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mis included parenthetically when applicable. †Comorbidity was not in the top 10 for this index condition (13).\u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAF indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.\u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# IMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs\u001b[0m\u001b[32m                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTwo general, but important, points emerge from the CMS data. First, a beneficiary with cardiovascular disease \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbut without at least 1 comorbid chronic condition is the exception rather than the rule. Second, whereas common\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrisk factors such as hypertension and hyperlipidemia are associated with the index cardiovascular conditions, \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe index conditions are associated with a constellation of comorbidities, the pathophysiology of which may be \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdistinct from the index condition and for which prevalence increases with age or other factors.\u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mOrganizations that develop CPGs must now consider comorbidities during the development process for \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdisease-specific CPGs. For high-prevalence index conditions, few CPGs address comorbidities (15), and even \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfewer provide guidance for patients with specific combinations of diseases. Managing patients with multiple \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions is more complex than managing patients with a single disease, and the presence of multiple \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconditions increases challenges for healthcare providers and patients. Comorbidities may constitute barriers to\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madherence to CPGs, and caring for patients with multiple comorbidities can affect patient safety if \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrecommendations for diagnosis and treatment in one CPG conflict with those for another condition (16). The \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcomplexity of various regimens for multiple comorbidities adds to the difficulty in patient management and \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32massessment of clinical outcomes (17). Furthermore, limited attention has been given to the physical, cognitive,\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msocial, psychological, and financial implications of managing comorbidities. Involving patients in the CPG \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdevelopment process, which the AHA/ACC recently initiated, is critically important to fully appreciate patient \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mperspectives (18,19).\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mCurrently, there are important challenges in addressing common comorbidities in the development and \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mimplementation\u001b[0m\u001b[32m                                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 73, N O . 24, 2019\u001b[0m\u001b[32m                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Grundy et al. e315\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 25, 2019: e 285 - 350\u001b[0m\u001b[32m                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m| |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|\u001b[0m\u001b[32m                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|\u001b[0m\u001b[32m                                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|TC|&lt;170 (&lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|\u001b[0m\u001b[32m                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Triglycerides (0-9 y)|&lt;75 (&lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|\u001b[0m\u001b[32m                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Triglycerides (10-19 y)|&lt;90 (&lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|\u001b[0m\u001b[32m                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|HDL-C|&gt;45 (&gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&lt;40 (&lt;1.0 mmol/L)|\u001b[0m\u001b[32m                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|LDL-C|&lt;110 (&lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\u001b[0m\u001b[32m                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Non–HDL-C|&lt;120 (&lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\u001b[0m\u001b[32m                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mValues given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m38.6; for triglycerides, divide by 88.6.\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mChildren. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfor LDL-C.\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m†The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles, \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrespectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNational Cholesterol Education Program; SI, Système international d’unités (International System of Units); and\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTC, total cholesterol.\u001b[0m\u001b[32m                                                                                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13). \u001b[0m\u001b[32m        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue \u001b[0m\u001b[32m             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.3-13—S4.4.4.3-16).\u001b[0m\u001b[32m                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhistory of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrelated genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).\u001b[0m\u001b[32m                         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mSubclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mconsidered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msuggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msevere hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mscreening), according to studies outside the United States demonstrating efficacy of this approach \u001b[0m\u001b[32m            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S4.4.4.3-37). Screening for severe\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 7 , N O . 4 , 2 0 2 1\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease\u001b[0m\u001b[32m                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcapacity or an abnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlimited value and does not show additive value for predicting clinical outcome when baseline measures of \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhemodynamic severity and functional status are considered. In addition, recording hemodynamics with exercise is\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mchallenging, and simpler parameters are adequate in most patients (2–4,6–11).\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAs reported in several prospective and retrospective studies, the risk of exercise testing is low in \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32masymptomatic patients with AS. However, exercise testing is avoided in symptomatic patients with AS because of \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32ma high risk of complications, including syncope, ventricular tachycardia, and death. In a prospective survey of\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m20 medical centers in Sweden that included 50,000 exercise tests done over an 18-month period, the complication\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrate was 18.4 per 10,000 tests; morbidity rate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests.\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAlthough the number of patients with AS was not reported, 12 of the 92 complications occurred in patients with \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mAS: 8 had a decline in blood pressure during exercise, 1 had asystole, and 3 had ventricular tachycardia \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(2,4,5,7–10,12).\u001b[0m\u001b[32m                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.2.2. Medical Therapy\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendations for Medical Therapy of AS\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mReferenced studies that support the recommendations are summarized in Online Data Supplement 5.\u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[32m                                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|\u001b[0m\u001b[32m                                                                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|1|B-NR|In patients at risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension should be treated according to standard GDMT, started at a low dose, and gradually titrated upward\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mas needed, with appropriate clinical monitoring (1–3).|\u001b[0m\u001b[32m                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|1|A|In all patients with calcific AS, statin therapy is indicated for primary and secondary prevention of \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32matherosclerosis on the basis of standard risk scores (4–6).|\u001b[0m\u001b[32m                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|2b|B-NR|In patients who have undergone TAVI, renin–angiotensin system blocker therapy (ACE inhibitor or ARB) \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmay be considered to reduce the long-term risk of all-cause mortality (7,8).|\u001b[0m\u001b[32m                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|3: No Benefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof hemodynamic progression of AS (4–6).|\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Synopsis\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mMedical treatment of hypertension and hyperlipidemia according to GDMT is appropriate for patients with AS. ACE\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32minhibitor or ARB treatment may reduce the mortality rate in patients with AS who underwent TAVI.\u001b[0m\u001b[32m               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Hypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32moverload on the LV in combination with valve obstruction. Concern that antihypertensive medications might \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mresult in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2 \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msmall RCTs, likely because AS does not result in “fixed” valve obstruction until late in the disease process. \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study, \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhigher mortality rate (both P<0.01) than those seen in normotensive patients with AS, although no impact on \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmortality was observed.\u001b[0m\u001b[32m                                                                                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. Concurrent CAD is common in patients with AS, and all patients should be screened and treated for \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of statin therapy for\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmild to moderate AS, although aortic valve event rates...\u001b[0m\u001b[32m                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# e300 Grundy et al.\u001b[0m\u001b[32m                                                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmay be indicated.\u001b[0m\u001b[32m                                                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Recommendation-Specific Supportive Text\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mbeen no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthose receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mexclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mfollow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgenetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mboth primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32madministered to patients with primary severe hypercholesterolemia.\u001b[0m\u001b[32m                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mgreater in the combined-therapy group, but there was no difference in carotid intima-media thickness between \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthe 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mplacebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years, \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mshowed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthan that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mindicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcharacteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve <50% \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mreduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6 \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLDL-C lowering (S4.2-9).\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mwith or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m4. PCSK9 inhibitors are promising drugs for treatment of FH\u001b[0m\u001b[32m                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6.\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012; \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m366:321–9.\u001b[0m\u001b[32m                                                                                                     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6.\u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mactivity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPromot. 2018. 890117118784226.\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[32m                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcarotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24.\u001b[0m\u001b[32m                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRevolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes. \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2009;4:205–14.\u001b[0m\u001b[32m                                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mlifestyle approach. J Clin Lipidol. 2014;8:181–6.\u001b[0m\u001b[32m                                                              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcardiovascular disease. Obesity (Silver Spring). 2015; 23:2109–17.\u001b[0m\u001b[32m                                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mand 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007; \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m116:1032–40.\u001b[0m\u001b[32m                                                                                                   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mdiet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIntervention Study in Children (DISC). Pediatrics. 2001;107:256–64.\u001b[0m\u001b[32m                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mof the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. \u001b[0m\u001b[32m                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m2011;96:E1999–2008.\u001b[0m\u001b[32m                                                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mblinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia. JAMA Pediatr. 2013;167:708–13.\u001b[0m\u001b[32m                                                           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmodification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122–3.\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mprofile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7.\u001b[0m\u001b[32m                        \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPaediatr. 1992;81:682–5.\u001b[0m\u001b[32m                                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemic children.\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Grundy et al.\u001b[0m\u001b[32m                                                                                                \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[32m                                                                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[32m                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[32m                                                                      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# Table 3 High-, Moderate-, and Low-Intensity Statin Therapy*\u001b[0m\u001b[32m                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|High Intensity| | |Moderate Intensity|Low Intensity|\u001b[0m\u001b[32m                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|---|---|---|---|---|\u001b[0m\u001b[32m                                                                                          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|LDL-C lowering†|≥50%| |30%–49%|&lt;30%|\u001b[0m\u001b[32m                                                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m|Statins|Atorvastatin (40 mg‡) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg (20 mg) Rosuvastatin (5 mg) \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m10 mg Simvastatin 20–40 mg§ Pravastatin 40 mg (80 mg) Lovastatin 40 mg (80 mg) Fluvastatin XL 80 mg Fluvastatin\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m40 mg BID Pitavastatin 1–4 mg|Simvastatin 10 mg Pravastatin 10–20 mg Lovastatin 20 mg Fluvastatin 20–40 mg| |\u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPercent LDL-C reductions with the primary statin medications used in clinical practice (atorvastatin, \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrosuvastatin, simvastatin) were estimated using the median reduction in LDL-C from the VOYAGER database \u001b[0m\u001b[32m       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S3.2.1-2). Reductions in LDL-C for other statin medications (fluvastatin, lovastatin, pitavastatin, \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mpravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mhypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type indicates specific statins and doses \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mthat were evaluated in RCTs (S3.2.1-3, S3.2.1-5—S3.2.1-16), and the Cholesterol Treatment Trialists’ 2010 \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mmeta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction in major cardiovascular events.\u001b[0m\u001b[32m             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m*Percent reductions are estimates from data across large populations. Individual responses to statin therapy \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mvaried in the RCTs and should be expected to vary in clinical practice (S3.2.1-2).\u001b[0m\u001b[32m                             \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m†LDL-C lowering that should occur with the dosage listed below each intensity.\u001b[0m\u001b[32m                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m‡Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mDecrease through Aggressive Lipid Lowering) study (S3.2.1-3).\u001b[0m\u001b[32m                                                  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m§Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrecommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis.\u001b[0m\u001b[32m                    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mBID indicates twice daily; FDA, U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mRCT, randomized controlled trial; VOYAGER, an individual patient data meta-analysis of statin therapy in \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mat-risk groups: effects of rosuvastatin, atorvastatin, and simvastatin; and XL, extended release.\u001b[0m\u001b[32m              \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m# 3.1.2. Lifestyle Therapies and Metabolic Syndrome\u001b[0m\u001b[32m                                                            \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m                                                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLifestyle therapies are particularly indicated for the metabolic syndrome, which is a cluster of risk factors \u001b[0m\u001b[32m \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32massociated with an increased risk of ASCVD, diabetes mellitus, and all-cause death (S3.1.2-1, S3.1.2-2). \u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mMetabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical definition of metabolic \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32msyndrome is that proposed by an international consortium of cardiovascular and diabetes organizations \u001b[0m\u001b[32m         \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mcircumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting \u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mglucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess weight and \u001b[0m\u001b[32m           \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mparticularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mamong both adults and children as levels of overweight and obesity have risen. Metabolic\u001b[0m\u001b[32m                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"FDA new hyperlipidemia drugs February 2025\"                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"FDA new hyperlipidemia drugs February 2025\"\u001b[0m\u001b[1;34m                                                        \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭──────────────────────────────────────────────</span> Tool Response Added <span style=\"color: #008000; text-decoration-color: #008000\">──────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Tool output added to messages:                                                                                  │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ In February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel third-generation │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ PCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density lipoprotein cholesterol     │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia.            │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ Lerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that does not require    │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ refrigeration. The FDA's action date for the review is set for December 12, 2025【0†source】【1†source】.       │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m─────────────────────────────────────────────\u001b[0m Tool Response Added \u001b[32m─────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mTool output added to messages:\u001b[0m\u001b[32m                                                                                 \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mIn February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel third-generation\u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mPCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density lipoprotein cholesterol \u001b[0m\u001b[32m   \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m(LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. \u001b[0m\u001b[32m          \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mLerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that does not require \u001b[0m\u001b[32m  \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32mrefrigeration. The FDA's action date for the review is set for December 12, 2025【0†source】【1†source】.\u001b[0m\u001b[32m      \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭───────────────────────────────────────────────</span> Current Messages <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Messages before API call:                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"system\",                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data' │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3)       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ times if needed, to gather all the context.\\nStop calling tools only when you have enough information to        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ provide a final, cohesive answer.\\nThen output your final answer to the user.\"                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"user\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"assistant\",                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": null,                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_calls\": [                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"lookup_patient_data\",                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName='Paul'\\\"}\"                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       },                                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_acc_guidelines\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"hyperlipidemia\\\"}\"                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       },                                                                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       {                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",                                                                  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"type\": \"function\",                                                                                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         \"function\": {                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"name\": \"search_bing_grounding\",                                                                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│           \"arguments\": \"{\\\"query\\\": \\\"FDA new hyperlipidemia drugs February 2025\\\"}\"                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│         }                                                                                                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│       }                                                                                                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     ]                                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"lookup_patient_data\",                                                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \" PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Notes\\n         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cove\\\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ year parent. Happen energy level anyone position. Few available thought world development.\"                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_acc_guidelines\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"received service or treatment for the specific condition. Detailed information on the           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ identification of chronic conditions is available from the CMS Chronic Conditions Data Warehouse (13).\\n\\n#     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Table 1\\n\\nTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ beneficiaries \\u202165 years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cardiovascular conditions were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with atrial fibrillation, and 1,145,719 with stroke. Two conditions that are major cardiovascular risk          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ factors\\u2014hypertension and hyperlipidemia\\u2014constitute the most frequent dyad. Hypertension,              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia, and ischemic heart disease were the 3 most prevalent comorbidities for patients with heart      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ failure, atrial fibrillation, and stroke, whereas hypertension, hyperlipidemia, and diabetes mellitus were the  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ most prevalent comorbidities in those with ischemic heart disease; however, arthritis, anemia, chronic          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ obstructive pulmonary disease, and Alzheimer\\u2019s disease also appeared.\\n\\n# Table 2\\n\\nTable 2 lists the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ top 5 most prevalent dyad and triad comorbidities for beneficiaries \\u202165 years of age with at least 2 (for  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood pressure, and         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ischemic heart disease were most frequently represented in the dyads and triads, with diabetes mellitus and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ arthritis completing the remaining prevalent combinations (14).\\nthan in former smokers, and there was a        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ significant relationship between the severity of carotid stenosis and pack-years of exposure to tobacco (239).  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ The RRs of finding 60% carotid stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ NOMASS and the BCID (Berlin Cerebral Ischemia Databank) studies, respectively (258).\\n\\n# 6.3. Control of       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hyperlipidemia\\n\\n# 6.3.1. Recommendations for Control of Hyperlipidemia\\n\\nCLASS I\\n\\n1. Treatment with a      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin medication is recommended for all patients with extracranial carotid or vertebral atherosclerosis to     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of Evidence: B)\\n\\nCLASS │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ IIa\\n\\n1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ vertebral atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL (259). (Level of Evidence: B)\\n2. If treatment with a statin (including trials of higher-dose statins and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ higher-potency statins) does not achieve the goal selected for a patient, intensifying LDL-lowering drug        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy with an additional drug from among those with evidence of improving outcomes (i.e., bile acid           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ sequestrants or niacin) can be effective (261\\u2013264). (Level of Evidence: B)\\n3. For patients who do not     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is reasonable (261,263,265).   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Level of Evidence: B)\\n\\nThe relationship between cholesterol and ischemic stroke is not as evident as that    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ between cholesterol and MI, and findings from population-based studies are inconsistent. In the MR FIT          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Multiple Risk Factor Intervention Trial), comprising more than 350,000 men, the RR of death increased          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ progressively with serum cholesterol, exceeding 2.5 in those with the highest levels (266). An analysis of 45   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ prospective observational cohorts involving approximately 450,000 individuals, however, found no association of │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia with stroke (267). In the ARIC study, the relationships between lipid values and incident  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ischemic.\\n# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\\n\\n# Grundy et al. e313\\n\\n# J U N E 25, 2 0 1 9 : e 2 8 5 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ - 3 5 0\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\nAs discussed in these guidelines (Section 4.2.) FH │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ often goes undiagnosed. Young adults with primary elevations of LDL-C \\u2265 190 mg/dl have a long-term ASCVD   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ burden (S4.4.4.2-3), and statin therapy is recommended. In adults with hypercholesterolemia, cascade screening  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ often identifies other family members with elevated LDL-C (Section 4.2.).\\n\\nHowever, even moderate             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). Secondary causes of elevated   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol\\u2014hypothyroidism (TSH), obstructive liver disease (liver panel), renal disease and nephrosis     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (creatinine and urine analysis) as well as dietary and medication history\\u2014should be addressed              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests genetic    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior to age 55 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive lifestyle      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\\n\\nA smaller     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia (LDL-C 160-189  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are present. Since │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ there is increased probability of genetic FH in this LDL-C range, clinical judgment would suggest that these    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section 4.2.). Indeed, it has   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ been shown that those with higher LDL-C can gain as much or more benefit from cholesterol reduction as do those │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\\n\\nIn young adults without           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ phenotypically severe hypercholesterolemia, risk assessment should begin by estimation of lifetime risk         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk starting at age 21 years │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (see Section 4.4.2.). This information can inform a focused risk discussion designed to improve high-risk       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet (S4.4.4.2-11, S4.4.4.2-12).     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ When young adults with hypercholesterolemia or multiple risk factors are identified, lifestyle intervention is  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicated. To date, no long-term RCTs with cholesterol-lowering drugs have been carried out in those 20 to 39   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ years age. However, a primary prevention RCT in those younger individuals at low to moderate short-term risk,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ but at high lifetime risk has been proposed (S4.4.4.2-13).\\n\\nOne approach to identifying young adults who      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ could benefit from statins or drug combination would be to detect significant coronary atherosclerosis with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ coronary artery calcium (CAC) scores. Its use for this purpose has been suggested (S4.4.4.2-14). But again,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ absence of RCT data precludes guideline recommendations at this time.\\n\\n# 4.4.4.3. Children and                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Adolescents\\n\\n# Recommendations for Children and Adolescents\\n\\nReferenced studies that support                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ recommendations are summarized in Online Data Supplements 18 to                                                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 21.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|A|In children and adolescents with lipid disorders related  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to obesity, it is recommended to intensify lifestyle therapy, including moderate caloric restriction and        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ regular aerobic physical activity (S4.4.4.3-1\\u2014S4.4.4.3-4).|\\n|I|B-NR|In children and adolescents with      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipid abnormalities, lifestyle counseling is beneficial for lowering LDL-C (S4.4.4.3-1\\u2014S4.4.4.3-3,\\nThe    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference,       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ children as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ one-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\\n\\n# 3.2. Lipid-Lowering            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Drugs\\n\\nAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ interventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Triglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ support their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ summarized in Table S3 in the Web Supplement.\\n\\n# 3.2.1. Statin Therapy\\n\\nThe intensity of statin therapy is  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ divided into 3 categories: high-intensity, moderate-intensity, and low-intensity (S3.2.1-1). High-intensity     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin therapy typically lowers LDL-C levels by \\u226550%, moderate-intensity statin therapy by 30% to 49%, and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ low-intensity statin therapy by &lt;30% (Table 3). Of course, the magnitude of LDL-C lowering will vary in         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ clinical practice (S3.2.1-2). Certain Asian populations may have a greater response to certain statins          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous (Table S4 in the Web Supplement). Statin  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ safety has been extensively evaluated (S3.2.1-19). Statin-associated side effects are discussed in Section 5.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Common medications that may potentially interact with statins are listed in Table S5 in the Web Supplement.     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ More information on statin drug\\u2013drug interactions can be obtained from the ACC LDL-C Manager               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.2.1-20).\\n\\n# 3.2.2. Nonstatin Therapies\\n\\nEzetimibe is the most commonly used nonstatin agent. It lowers  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LDL-C levels by 13% to 20% and has a low incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduce LDL-C levels by 15% to 30% depending on the dose. Bile acid sequestrants are not absorbed and do not     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cause systemic side effects, but they are associated with gastrointestinal complaints (e.g., constipation) and  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ can cause severe hypertriglyceridemia when fasting triglycerides are \\u2265300 mg/dL (\\u22653.4 mmol/L). PCSK9  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitors are powerful LDL-lowering drugs.\\n# J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4\\n\\n# O C T O B E R 2 8 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ , 2 0 1 4 : 1 8 5 1 \\u2013 6\\n\\n# AHA/ACC/HHS Strategies on Comorbidities\\n\\n# T A B L E 1 The 10 Most Common   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Comorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare Beneficiaries $65 Years of Age      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (13)\\n\\n|Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ = 1,145,719)|\\n|---|---|---|---|---|\\n|Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|\\n|Hyperlipidemia|2     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (69.1)|3 (62.6)|2 (64.4)|2 (69.9)|\\n|Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|\\n|Arthritis|4       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (40.6)|6 (45.6)|6 (41.7)|5 (44.2)|\\n|Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|\\n|HF|6 (36.3)|Index|4 (50.9)|7 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (37.2)|\\n|Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|\\n|Chronic kidney disease|7 (30.2)|7 (44.8)|8 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (34.4)|8 (35.2)|\\n|Cataract|8 (21.6)|\\u2020|10 (22.6)|\\u2020|\\n|COPD|9 (21.0)|8 (30.9)|9 (23.8)|\\u2020|\\n|AF|10 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (18.7)|9 (28.8)|Index|\\u2020|\\n|Alzheimer\\u2019s disease/dementia|\\u2020|10 (26.3)|\\u2020|9                     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (33.8)|\\n|Depression|\\u2020|\\u2020|\\u2020|10 (29.7)|\\n|Stroke|\\u2020|\\u2020|\\u2020|Index|\\n\\n*Data shown as     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rank and percentage of persons with index condition who also had a comorbidity. The percentage is included      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ parenthetically when applicable. \\u2020Comorbidity was not in the top 10 for this index condition (13).\\n\\nAF   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.\\n\\n#         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ IMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs\\n\\nTwo general, but important, points emerge from │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the CMS data. First, a beneficiary with cardiovascular disease but without at least 1 comorbid chronic          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ condition is the exception rather than the rule. Second, whereas common risk factors such as hypertension and   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia are associated with the index cardiovascular conditions, the index conditions are associated     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with a constellation of comorbidities, the pathophysiology of which may be distinct from the index condition    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and for which prevalence increases with age or other factors.\\n\\nOrganizations that develop CPGs must now       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ consider comorbidities during the development process for disease-specific CPGs. For high-prevalence index      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ conditions, few CPGs address comorbidities (15), and even fewer provide guidance for patients with specific     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ combinations of diseases. Managing patients with multiple conditions is more complex than managing patients     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ with a single disease, and the presence of multiple conditions increases challenges for healthcare providers    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and patients. Comorbidities may constitute barriers to adherence to CPGs, and caring for patients with multiple │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ comorbidities can affect patient safety if recommendations for diagnosis and treatment in one CPG conflict with │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ those for another condition (16). The complexity of various regimens for multiple comorbidities adds to the     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ difficulty in patient management and assessment of clinical outcomes (17). Furthermore, limited attention has   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ been given to the physical, cognitive, social, psychological, and financial implications of managing            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ comorbidities. Involving patients in the CPG development process, which the AHA/ACC recently initiated, is      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ critically important to fully appreciate patient perspectives (18,19).\\n\\nCurrently, there are important        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ challenges in addressing common comorbidities in the development and implementation\\n# J A C C V O L . 73, N O  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ . 24, 2019\\n\\n# Grundy et al. e315\\n\\n# J U N E 25, 2019: e 285 - 350\\n\\n# 2018 Cholesterol Clinical Practice   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Guideline\\n\\n# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\\n\\n| |Acceptable, mg/dL|Borderline,   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mg/dL|Abnormal, mg/dL|\\n|---|---|---|---|\\n|TC|&amp;lt;170 (&amp;lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmol/L)|\\n|Triglycerides (0-9 y)|&amp;lt;75 (&amp;lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1                      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmol/L)|\\n|Triglycerides (10-19 y)|&amp;lt;90 (&amp;lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmol/L)|\\n|HDL-C|&amp;gt;45 (&amp;gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&amp;lt;40 (&amp;lt;1.0 mmol/L)|\\n|LDL-C|&amp;lt;110        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (&amp;lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\\n|Non\\u2013HDL-C|&amp;lt;120 (&amp;lt;3.1 mmol/L)|120-144 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\\n\\nValues given are in mg/dL. To convert to SI units, divide the results   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for TC, LDL-C, HDL-C, and non\\u2013HDL-C by 38.6; for triglycerides, divide by 88.6.\\n\\n*Values for plasma      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in Children. Non\\u2013HDL-C   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints for                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LDL-C.\\n\\n\\u2020The cutpoints for high and borderline high represent approximately the 95th and 75th            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ percentiles, respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\\n\\nHDL-C        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, National      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cholesterol Education Program; SI, Syst\\u00e8me international d\\u2019unit\\u00e9s (International System of       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Units); and TC, total cholesterol.\\n\\nHypercholesterolemia show reasonable LDL-C lowering with no significant   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adverse effects (S4.4.4.3-13). Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerability is an issue (S4.4.4.3-13\\u2014S4.4.4.3-16).\\n\\n4. Lipid testing during childhood can identify the  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe hypercholesterolemia, which includes FH, can be     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ identified in children and adolescents with an LDL-C level $190 mg/dL ($4.9 mmol/L). Moreover, children and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family history of early atherosclerosis or similarly      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated cholesterol in 1 parent likely are those with FH and related genetic disorders associated with         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ accelerated ASCVD (S4.4.4.3-17\\u2014S4.4.4.3-21).\\n\\nSubclinical atherosclerosis data suggest divergence        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ between affected and unaffected children and adolescents beginning at age 10 years (S4.4.4.3-28), which         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ supports screening by this age, although this topic is still considered controversial (S4.4.4.3-36). Screening  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ is advised beginning at age 2 years if a family history is suggestive of either early CVD or significant        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ primary hypercholesterolemia. Identification of a child with severe hypercholesterolemia should prompt          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ screening of extended family members (e.g., reverse-cascade screening), according to studies outside the United │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ States demonstrating efficacy of this approach (S4.4.4.3-37). Screening for severe\\n# J A C C V O L . 7 7 , N O │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ . 4 , 2 0 2 1\\n\\n# 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease\\n\\ncapacity or an        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ abnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of limited value and     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ does not show additive value for predicting clinical outcome when baseline measures of hemodynamic severity and │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ functional status are considered. In addition, recording hemodynamics with exercise is challenging, and simpler │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ parameters are adequate in most patients (2\\u20134,6\\u201311).\\n\\nAs reported in several prospective and        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ retrospective studies, the risk of exercise testing is low in asymptomatic patients with AS. However, exercise  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ testing is avoided in symptomatic patients with AS because of a high risk of complications, including syncope,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ventricular tachycardia, and death. In a prospective survey of 20 medical centers in Sweden that included       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 50,000 exercise tests done over an 18-month period, the complication rate was 18.4 per 10,000 tests; morbidity  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests. Although the number of patients with AS   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ was not reported, 12 of the 92 complications occurred in patients with AS: 8 had a decline in blood pressure    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ during exercise, 1 had asystole, and 3 had ventricular tachycardia (2,4,5,7\\u201310,12).\\n\\n# 3.2.2. Medical    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Therapy\\n\\n# Recommendations for Medical Therapy of AS\\n\\nReferenced studies that support the recommendations   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ are summarized in Online Data Supplement 5.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|1|B-NR|In patients at │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), hypertension should be   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ treated according to standard GDMT, started at a low dose, and gradually titrated upward as needed, with        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ appropriate clinical monitoring (1\\u20133).|\\n|1|A|In all patients with calcific AS, statin therapy is          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicated for primary and secondary prevention of atherosclerosis on the basis of standard risk scores          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (4\\u20136).|\\n|2b|B-NR|In patients who have undergone TAVI, renin\\u2013angiotensin system blocker therapy (ACE  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitor or ARB) may be considered to reduce the long-term risk of all-cause mortality (7,8).|\\n|3: No         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Benefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention of      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hemodynamic progression of AS (4\\u20136).|\\n\\n# Synopsis\\n\\nMedical treatment of hypertension and               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia according to GDMT is appropriate for patients with AS. ACE inhibitor or ARB treatment may reduce │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the mortality rate in patients with AS who underwent TAVI.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Hypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ overload on the LV in combination with valve obstruction. Concern that antihypertensive medications might       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ result in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ small RCTs, likely because AS does not result in \\u201cfixed\\u201d valve obstruction until late in the disease  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ process. In 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ higher mortality rate (both P&lt;0.01) than those seen in normotensive patients with AS, although no impact on     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mortality was observed.\\n\\n2. Concurrent CAD is common in patients with AS, and all patients should be screened │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ and treated for hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin therapy for mild to moderate AS, although aortic valve event rates...\\n# e300 Grundy et al.\\n\\n# J A C C │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ V O L . 7 3 , N O . 2 4 , 2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ : e 2 8 5 - 3 5 0\\n\\nLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to a lipid specialist may be indicated.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. Patients with        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ primary severe hypercholesterolemia (LDL-C levels \\u2265190 mg/dL [\\u22654.9 mmol/L]) have a high-risk of ASCVD │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have been no     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\u2265190 mg/dL (\\u22654.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ baseline LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ death in those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of 2,560 exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ long-term follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ therapy reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ phenotypic or genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ASCVD risk in both primary- and secondary-prevention trials and because high-intensity statins provide greater  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ASCVD risk reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ should be administered to patients with primary severe hypercholesterolemia.\\n2. A large placebo-controlled RCT │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 mg daily, on carotid intima-media  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was greater in the combined-therapy group, │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ but there was no difference in carotid intima-media thickness between the 2 groups. The study was not powered   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to examine the risk of ASCVD events (S4.2-10). However, a very large placebo-controlled RCT examining ASCVD     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ outcomes in post-ACS patients, performed over a period of 7 years, showed that the addition of ezetimibe 10 mg  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to simvastatin 40 mg daily resulted in greater ASCVD risk reduction than that produced by statin monotherapy    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S4.2-8). Secondary-prevention patients with certain ASCVD risk indicators exhibit greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ from ezetimibe therapy than do patients without these characteristics (S4.2-20). Patients with severe           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia who are adherent to statins, achieve &lt;50% reduction in LDL-C levels with maximally         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ tolerated statin therapy, and have an LDL-C level \\u2265100 mg/dL (\\u22652.6 mmol/L) are likely to derive       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ additional ASCVD risk reduction from ezetimibe add-on therapy through additional LDL-C lowering (S4.2-9).\\n3.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins with  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\\n4.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ PCSK9 inhibitors are promising drugs for treatment of FH\\nprevention of cardiovascular disease: an opportunity  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ to harmonize guidelines. JAMA Cardiol. 2017;2:1175\\u20136.\\n\\nS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Lifetime risks of cardiovascular disease. N Engl J Med. 2012; 366:321\\u20139.\\n\\nS4.4.4.2-11. Lehr AL, Driver   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505\\u20136.\\n\\nS4.4.4.2-12. Omura JD,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Watson KB, Loustalot F, et al. Primary care providers\\u2019 awareness of physical activity-related intensive    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ behavioral counseling services for cardiovascular disease prevention. Am J Health Promot. 2018.                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 890117118784226.\\n\\n# 4.4.4.3. Children and Adolescents\\n\\nS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Heart Vessels. 2009;24:419\\u201324.\\n\\nS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ intervention using Dance Dance Revolution on endothelial function and other risk factors in overweight          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ children. Int J Pediatr Obes. 2009;4:205\\u201314.\\n\\nS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol.                       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2014;8:181\\u20136.\\n\\nS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109\\u201317.\\n\\nS4.4.4.3-5.  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;                │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 116:1032\\u201340.\\n\\nS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256\\u201364.\\n\\nS4.4.4.3-7. Dorgan JF,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab.                                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2011;96:E1999\\u20132008.\\n\\nS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708\\u201313.\\n\\nS4.4.4.3-9.      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification:     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122\\u20133.\\n\\nS4.4.4.3-10. Torvik K, Narverud I, │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Ottestad I, et al. Dietary counseling is associated with an improved lipid profile in children with familial    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hypercholesterolemia. Atherosclerosis. 2016;252:21\\u20137.\\n\\nS4.4.4.3-11. Koletzko B, Kupke I, Wendel U.       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr.                                   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 1992;81:682\\u20135.\\n\\nS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ nutrition education for hypercholesterolemic children.\\n# Grundy et al.\\n\\n# J A C C V O L . 7 3 , N O . 2 4 ,  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\\n\\n#     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Table 3 High-, Moderate-, and Low-Intensity Statin Therapy*\\n\\n|High Intensity| | |Moderate Intensity|Low       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Intensity|\\n|---|---|---|---|---|\\n|LDL-C lowering\\u2020|\\u226550%|                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ |30%\\u201349%|&amp;lt;30%|\\n|Statins|Atorvastatin (40 mg\\u2021) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (20 mg) Rosuvastatin (5 mg) 10 mg Simvastatin 20\\u201340 mg\\u00a7 Pravastatin 40 mg (80 mg) Lovastatin 40 mg    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (80 mg) Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 1\\u20134 mg|Simvastatin 10 mg Pravastatin       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 10\\u201320 mg Lovastatin 20 mg Fluvastatin 20\\u201340 mg| |\\n\\nPercent LDL-C reductions with the primary statin │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medications used in clinical practice (atorvastatin, rosuvastatin, simvastatin) were estimated using the median │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ reduction in LDL-C from the VOYAGER database (S3.2.1-2). Reductions in LDL-C for other statin medications       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (fluvastatin, lovastatin, pitavastatin, pravastatin) were identified according to FDA-approved product labeling │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in adults with hyperlipidemia, primary hypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ indicates specific statins and doses that were evaluated in RCTs (S3.2.1-3, S3.2.1-5\\u2014S3.2.1-16), and the   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Cholesterol Treatment Trialists\\u2019 2010 meta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ in major cardiovascular events.\\n\\n*Percent reductions are estimates from data across large populations.        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.2.1-2).\\n\\n\\u2020LDL-C lowering that should occur with the dosage listed below each                         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ intensity.\\n\\n\\u2021Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ IDEAL (Incremental Decrease through Aggressive Lipid Lowering) study (S3.2.1-3).\\n\\n\\u00a7Although simvastatin  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ FDA because of the increased risk of myopathy, including rhabdomyolysis.\\n\\nBID indicates twice daily; FDA,     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ U.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ trial; VOYAGER, an individual patient data meta-analysis of statin therapy in at-risk groups: effects of        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ rosuvastatin, atorvastatin, and simvastatin; and XL, extended release.\\n\\n# 3.1.2. Lifestyle Therapies and      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Metabolic Syndrome\\n\\nLifestyle therapies are particularly indicated for the metabolic syndrome, which is a     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cluster of risk factors associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (S3.1.2-1, S3.1.2-2). Metabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ definition of metabolic syndrome is that proposed by an international consortium of cardiovascular and diabetes │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ organizations (S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors:       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated waist circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ elevated fasting glucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ weight and particularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ risen sharply among both adults and children as levels of overweight and obesity have risen. Metabolic\"         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   },                                                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   {                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"role\": \"tool\",                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"tool_call_id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"name\": \"search_bing_grounding\",                                                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│     \"content\": \"In February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ third-generation PCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia. Lerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ does not require refrigeration. The FDA's action date for the review is set for December 12,                    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2025\\u30100\\u2020source\\u3011\\u30101\\u2020source\\u3011.\"                                                        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│   }                                                                                                             │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ]                                                                                                               │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m──────────────────────────────────────────────\u001b[0m Current Messages \u001b[2m───────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMessages before API call:\u001b[0m\u001b[2m                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"system\",\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"You are a cardiology-focused AI assistant with access to three tools:\\n1) 'lookup_patient_data'\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor querying patient records from Azure SQL.\\n2) 'search_acc_guidelines' for official ACC guidelines.\\n3) \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m'search_bing_grounding' for real-time public information.\\n\\nYou can call these tools in any order, multiple \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtimes if needed, to gather all the context.\\nStop calling tools only when you have enough information to \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprovide a final, cohesive answer.\\nThen output your final answer to the user.\"\u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"user\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myou confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthere are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\"\u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"assistant\",\u001b[0m\u001b[2m                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": null,\u001b[0m\u001b[2m                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_calls\": [\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"SELECT * FROM PatientMedicalData WHERE FirstName='Gloria' AND \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName='Paul'\\\"}\"\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      },\u001b[0m\u001b[2m                                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"hyperlipidemia\\\"}\"\u001b[0m\u001b[2m                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      },\u001b[0m\u001b[2m                                                                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      {\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",\u001b[0m\u001b[2m                                                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"type\": \"function\",\u001b[0m\u001b[2m                                                                                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        \"function\": {\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m          \"arguments\": \"{\\\"query\\\": \\\"FDA new hyperlipidemia drugs February 2025\\\"}\"\u001b[0m\u001b[2m                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m        }\u001b[0m\u001b[2m                                                                                                      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m      }\u001b[0m\u001b[2m                                                                                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    ]\u001b[0m\u001b[2m                                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_wDYynvTCJlXDSeGHihDW3rof\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"lookup_patient_data\",\u001b[0m\u001b[2m                                                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \" PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNotes\\n         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCove\\\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myear parent. Happen energy level anyone position. Few available thought world development.\"\u001b[0m\u001b[2m                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_AcZAtI7rblAPdmxzoC6nxGgg\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_acc_guidelines\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"received service or treatment for the specific condition. Detailed information on the \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2midentification of chronic conditions is available from the CMS Chronic Conditions Data Warehouse (13).\\n\\n# \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTable 1\\n\\nTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeneficiaries \\u202165 years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcardiovascular conditions were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith atrial fibrillation, and 1,145,719 with stroke. Two conditions that are major cardiovascular risk \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfactors\\u2014hypertension and hyperlipidemia\\u2014constitute the most frequent dyad. Hypertension, \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia, and ischemic heart disease were the 3 most prevalent comorbidities for patients with heart \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfailure, atrial fibrillation, and stroke, whereas hypertension, hyperlipidemia, and diabetes mellitus were the \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmost prevalent comorbidities in those with ischemic heart disease; however, arthritis, anemia, chronic \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mobstructive pulmonary disease, and Alzheimer\\u2019s disease also appeared.\\n\\n# Table 2\\n\\nTable 2 lists the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtop 5 most prevalent dyad and triad comorbidities for beneficiaries \\u202165 years of age with at least 2 (for \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood pressure, and \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mischemic heart disease were most frequently represented in the dyads and triads, with diabetes mellitus and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2marthritis completing the remaining prevalent combinations (14).\\nthan in former smokers, and there was a \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msignificant relationship between the severity of carotid stenosis and pack-years of exposure to tobacco (239). \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mThe RRs of finding 60% carotid stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNOMASS and the BCID (Berlin Cerebral Ischemia Databank) studies, respectively (258).\\n\\n# 6.3. Control of \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHyperlipidemia\\n\\n# 6.3.1. Recommendations for Control of Hyperlipidemia\\n\\nCLASS I\\n\\n1. Treatment with a \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin medication is recommended for all patients with extracranial carotid or vertebral atherosclerosis to \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of Evidence: B)\\n\\nCLASS\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIIa\\n\\n1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mvertebral atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL (259). (Level of Evidence: B)\\n2. If treatment with a statin (including trials of higher-dose statins and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigher-potency statins) does not achieve the goal selected for a patient, intensifying LDL-lowering drug \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy with an additional drug from among those with evidence of improving outcomes (i.e., bile acid \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msequestrants or niacin) can be effective (261\\u2013264). (Level of Evidence: B)\\n3. For patients who do not \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is reasonable (261,263,265). \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Level of Evidence: B)\\n\\nThe relationship between cholesterol and ischemic stroke is not as evident as that \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetween cholesterol and MI, and findings from population-based studies are inconsistent. In the MR FIT \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Multiple Risk Factor Intervention Trial), comprising more than 350,000 men, the RR of death increased \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprogressively with serum cholesterol, exceeding 2.5 in those with the highest levels (266). An analysis of 45 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprospective observational cohorts involving approximately 450,000 individuals, however, found no association of\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia with stroke (267). In the ARIC study, the relationships between lipid values and incident \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mischemic.\\n# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\\n\\n# Grundy et al. e313\\n\\n# J U N E 25, 2 0 1 9 : e 2 8 5\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m- 3 5 0\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\nAs discussed in these guidelines (Section 4.2.) FH\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moften goes undiagnosed. Young adults with primary elevations of LDL-C \\u2265 190 mg/dl have a long-term ASCVD \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mburden (S4.4.4.2-3), and statin therapy is recommended. In adults with hypercholesterolemia, cascade screening \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moften identifies other family members with elevated LDL-C (Section 4.2.).\\n\\nHowever, even moderate \u001b[0m\u001b[2m           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). Secondary causes of elevated \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol\\u2014hypothyroidism (TSH), obstructive liver disease (liver panel), renal disease and nephrosis \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(creatinine and urine analysis) as well as dietary and medication history\\u2014should be addressed \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mappropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests genetic \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mforms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior to age 55\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive lifestyle \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchange has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\\n\\nA smaller \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mgroup, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia (LDL-C 160-189 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are present. Since\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthere is increased probability of genetic FH in this LDL-C range, clinical judgment would suggest that these \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigh risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section 4.2.). Indeed, it has \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeen shown that those with higher LDL-C can gain as much or more benefit from cholesterol reduction as do those\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\\n\\nIn young adults without \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mphenotypically severe hypercholesterolemia, risk assessment should begin by estimation of lifetime risk \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk starting at age 21 years\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(see Section 4.4.2.). This information can inform a focused risk discussion designed to improve high-risk \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet (S4.4.4.2-11, S4.4.4.2-12). \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mWhen young adults with hypercholesterolemia or multiple risk factors are identified, lifestyle intervention is \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicated. To date, no long-term RCTs with cholesterol-lowering drugs have been carried out in those 20 to 39 \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2myears age. However, a primary prevention RCT in those younger individuals at low to moderate short-term risk, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbut at high lifetime risk has been proposed (S4.4.4.2-13).\\n\\nOne approach to identifying young adults who \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcould benefit from statins or drug combination would be to detect significant coronary atherosclerosis with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcoronary artery calcium (CAC) scores. Its use for this purpose has been suggested (S4.4.4.2-14). But again, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mabsence of RCT data precludes guideline recommendations at this time.\\n\\n# 4.4.4.3. Children and \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mAdolescents\\n\\n# Recommendations for Children and Adolescents\\n\\nReferenced studies that support \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrecommendations are summarized in Online Data Supplements 18 to \u001b[0m\u001b[2m                                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m21.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|I|A|In children and adolescents with lipid disorders related \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto obesity, it is recommended to intensify lifestyle therapy, including moderate caloric restriction and \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mregular aerobic physical activity (S4.4.4.3-1\\u2014S4.4.4.3-4).|\\n|I|B-NR|In children and adolescents with \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipid abnormalities, lifestyle counseling is beneficial for lowering LDL-C (S4.4.4.3-1\\u2014S4.4.4.3-3,\\nThe \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdiagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference, \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mobesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchildren as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mone-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\\n\\n# 3.2. Lipid-Lowering \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mDrugs\\n\\nAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minterventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTriglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msupport their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msummarized in Table S3 in the Web Supplement.\\n\\n# 3.2.1. Statin Therapy\\n\\nThe intensity of statin therapy is \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdivided into 3 categories: high-intensity, moderate-intensity, and low-intensity (S3.2.1-1). High-intensity \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin therapy typically lowers LDL-C levels by \\u226550%, moderate-intensity statin therapy by 30% to 49%, and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlow-intensity statin therapy by <30% (Table 3). Of course, the magnitude of LDL-C lowering will vary in \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mclinical practice (S3.2.1-2). Certain Asian populations may have a greater response to certain statins \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous (Table S4 in the Web Supplement). Statin \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msafety has been extensively evaluated (S3.2.1-19). Statin-associated side effects are discussed in Section 5. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCommon medications that may potentially interact with statins are listed in Table S5 in the Web Supplement. \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMore information on statin drug\\u2013drug interactions can be obtained from the ACC LDL-C Manager \u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.2.1-20).\\n\\n# 3.2.2. Nonstatin Therapies\\n\\nEzetimibe is the most commonly used nonstatin agent. It lowers \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLDL-C levels by 13% to 20% and has a low incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduce LDL-C levels by 15% to 30% depending on the dose. Bile acid sequestrants are not absorbed and do not \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcause systemic side effects, but they are associated with gastrointestinal complaints (e.g., constipation) and \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcan cause severe hypertriglyceridemia when fasting triglycerides are \\u2265300 mg/dL (\\u22653.4 mmol/L). PCSK9 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitors are powerful LDL-lowering drugs.\\n# J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4\\n\\n# O C T O B E R 2 8\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m, 2 0 1 4 : 1 8 5 1 \\u2013 6\\n\\n# AHA/ACC/HHS Strategies on Comorbidities\\n\\n# T A B L E 1 The 10 Most Common \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mComorbidities for 4 Index Cardiovascular Conditions: 2012 Data for Medicare Beneficiaries $65 Years of Age \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(13)\\n\\n|Comorbidity|Ischemic Heart Disease* (N = 8,678,060)|HF* (N = 4,366,489)|AF* (N = 2,556,839)|Stroke* (N\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m= 1,145,719)|\\n|---|---|---|---|---|\\n|Hypertension|1 (81.3)|1 (85.6)|1 (84.5)|1 (89.0)|\\n|Hyperlipidemia|2 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(69.1)|3 (62.6)|2 (64.4)|2 (69.9)|\\n|Diabetes mellitus|3 (41.7)|5 (47.1)|7 (37.1)|6 (41.5)|\\n|Arthritis|4 \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(40.6)|6 (45.6)|6 (41.7)|5 (44.2)|\\n|Anemia|5 (38.7)|4 (51.2)|5 (43.0)|4 (46.8)|\\n|HF|6 (36.3)|Index|4 (50.9)|7\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(37.2)|\\n|Ischemic heart disease|Index|2 (72.1)|3 (63.5)|3 (58.1)|\\n|Chronic kidney disease|7 (30.2)|7 (44.8)|8\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(34.4)|8 (35.2)|\\n|Cataract|8 (21.6)|\\u2020|10 (22.6)|\\u2020|\\n|COPD|9 (21.0)|8 (30.9)|9 (23.8)|\\u2020|\\n|AF|10\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(18.7)|9 (28.8)|Index|\\u2020|\\n|Alzheimer\\u2019s disease/dementia|\\u2020|10 (26.3)|\\u2020|9 \u001b[0m\u001b[2m                   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(33.8)|\\n|Depression|\\u2020|\\u2020|\\u2020|10 (29.7)|\\n|Stroke|\\u2020|\\u2020|\\u2020|Index|\\n\\n*Data shown as \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrank and percentage of persons with index condition who also had a comorbidity. The percentage is included \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mparenthetically when applicable. \\u2020Comorbidity was not in the top 10 for this index condition (13).\\n\\nAF \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; and HF, heart failure.\\n\\n# \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIMPLICATIONS AND FUTURE DIRECTIONS IN THE DEVELOPMENT OF CPGs\\n\\nTwo general, but important, points emerge from\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe CMS data. First, a beneficiary with cardiovascular disease but without at least 1 comorbid chronic \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcondition is the exception rather than the rule. Second, whereas common risk factors such as hypertension and \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia are associated with the index cardiovascular conditions, the index conditions are associated \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith a constellation of comorbidities, the pathophysiology of which may be distinct from the index condition \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand for which prevalence increases with age or other factors.\\n\\nOrganizations that develop CPGs must now \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mconsider comorbidities during the development process for disease-specific CPGs. For high-prevalence index \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mconditions, few CPGs address comorbidities (15), and even fewer provide guidance for patients with specific \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcombinations of diseases. Managing patients with multiple conditions is more complex than managing patients \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwith a single disease, and the presence of multiple conditions increases challenges for healthcare providers \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand patients. Comorbidities may constitute barriers to adherence to CPGs, and caring for patients with multiple\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcomorbidities can affect patient safety if recommendations for diagnosis and treatment in one CPG conflict with\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthose for another condition (16). The complexity of various regimens for multiple comorbidities adds to the \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdifficulty in patient management and assessment of clinical outcomes (17). Furthermore, limited attention has \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbeen given to the physical, cognitive, social, psychological, and financial implications of managing \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcomorbidities. Involving patients in the CPG development process, which the AHA/ACC recently initiated, is \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcritically important to fully appreciate patient perspectives (18,19).\\n\\nCurrently, there are important \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchallenges in addressing common comorbidities in the development and implementation\\n# J A C C V O L . 73, N O \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m. 24, 2019\\n\\n# Grundy et al. e315\\n\\n# J U N E 25, 2019: e 285 - 350\\n\\n# 2018 Cholesterol Clinical Practice \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mGuideline\\n\\n# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\\n\\n| |Acceptable, mg/dL|Borderline, \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmg/dL|Abnormal, mg/dL|\\n|---|---|---|---|\\n|TC|&lt;170 (&lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmol/L)|\\n|Triglycerides (0-9 y)|&lt;75 (&lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 \u001b[0m\u001b[2m                    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmol/L)|\\n|Triglycerides (10-19 y)|&lt;90 (&lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 \u001b[0m\u001b[2m                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmol/L)|\\n|HDL-C|&gt;45 (&gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&lt;40 (&lt;1.0 mmol/L)|\\n|LDL-C|&lt;110 \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(&lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\\n|Non\\u2013HDL-C|&lt;120 (&lt;3.1 mmol/L)|120-144\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\\n\\nValues given are in mg/dL. To convert to SI units, divide the results \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor TC, LDL-C, HDL-C, and non\\u2013HDL-C by 38.6; for triglycerides, divide by 88.6.\\n\\n*Values for plasma \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in Children. Non\\u2013HDL-C \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mvalues from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints for \u001b[0m\u001b[2m                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLDL-C.\\n\\n\\u2020The cutpoints for high and borderline high represent approximately the 95th and 75th \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpercentiles, respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\\n\\nHDL-C \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, National \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCholesterol Education Program; SI, Syst\\u00e8me international d\\u2019unit\\u00e9s (International System of \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mUnits); and TC, total cholesterol.\\n\\nHypercholesterolemia show reasonable LDL-C lowering with no significant \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madverse effects (S4.4.4.3-13). Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerability is an issue (S4.4.4.3-13\\u2014S4.4.4.3-16).\\n\\n4. Lipid testing during childhood can identify the \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msevere hypercholesterolemia phenotype (S4.4.4.3-35). Severe hypercholesterolemia, which includes FH, can be \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2midentified in children and adolescents with an LDL-C level $190 mg/dL ($4.9 mmol/L). Moreover, children and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family history of early atherosclerosis or similarly \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated cholesterol in 1 parent likely are those with FH and related genetic disorders associated with \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maccelerated ASCVD (S4.4.4.3-17\\u2014S4.4.4.3-21).\\n\\nSubclinical atherosclerosis data suggest divergence \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbetween affected and unaffected children and adolescents beginning at age 10 years (S4.4.4.3-28), which \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msupports screening by this age, although this topic is still considered controversial (S4.4.4.3-36). Screening \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mis advised beginning at age 2 years if a family history is suggestive of either early CVD or significant \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprimary hypercholesterolemia. Identification of a child with severe hypercholesterolemia should prompt \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mscreening of extended family members (e.g., reverse-cascade screening), according to studies outside the United\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mStates demonstrating efficacy of this approach (S4.4.4.3-37). Screening for severe\\n# J A C C V O L . 7 7 , N O\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m. 4 , 2 0 2 1\\n\\n# 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease\\n\\ncapacity or an \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mabnormal blood pressure response. Recording aortic valve hemodynamics with exercise is of limited value and \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdoes not show additive value for predicting clinical outcome when baseline measures of hemodynamic severity and\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunctional status are considered. In addition, recording hemodynamics with exercise is challenging, and simpler\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mparameters are adequate in most patients (2\\u20134,6\\u201311).\\n\\nAs reported in several prospective and \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mretrospective studies, the risk of exercise testing is low in asymptomatic patients with AS. However, exercise \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtesting is avoided in symptomatic patients with AS because of a high risk of complications, including syncope, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mventricular tachycardia, and death. In a prospective survey of 20 medical centers in Sweden that included \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m50,000 exercise tests done over an 18-month period, the complication rate was 18.4 per 10,000 tests; morbidity \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrate, 5.2 per 10,000 tests; and mortality rate, 0.4 per 10,000 tests. Although the number of patients with AS \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mwas not reported, 12 of the 92 complications occurred in patients with AS: 8 had a decline in blood pressure \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mduring exercise, 1 had asystole, and 3 had ventricular tachycardia (2,4,5,7\\u201310,12).\\n\\n# 3.2.2. Medical \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTherapy\\n\\n# Recommendations for Medical Therapy of AS\\n\\nReferenced studies that support the recommendations \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mare summarized in Online Data Supplement 5.\\n\\n|COR|LOE|RECOMMENDATIONS|\\n|---|---|---|\\n|1|B-NR|In patients at\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisk of developing AS (Stage A) and in patients with asymptomatic AS (Stages B and C), hypertension should be \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtreated according to standard GDMT, started at a low dose, and gradually titrated upward as needed, with \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mappropriate clinical monitoring (1\\u20133).|\\n|1|A|In all patients with calcific AS, statin therapy is \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicated for primary and secondary prevention of atherosclerosis on the basis of standard risk scores \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(4\\u20136).|\\n|2b|B-NR|In patients who have undergone TAVI, renin\\u2013angiotensin system blocker therapy (ACE \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitor or ARB) may be considered to reduce the long-term risk of all-cause mortality (7,8).|\\n|3: No \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mBenefit|A|In patients with calcific AS (Stages B and C), statin therapy is not indicated for prevention of \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhemodynamic progression of AS (4\\u20136).|\\n\\n# Synopsis\\n\\nMedical treatment of hypertension and \u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia according to GDMT is appropriate for patients with AS. ACE inhibitor or ARB treatment may reduce\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe mortality rate in patients with AS who underwent TAVI.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHypertension is common in patients with AS, may be a risk factor for AS, and adds to the total pressure \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moverload on the LV in combination with valve obstruction. Concern that antihypertensive medications might \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mresult in a decrease in cardiac output has not been corroborated in studies of medical therapy, including 2 \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2msmall RCTs, likely because AS does not result in \\u201cfixed\\u201d valve obstruction until late in the disease \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprocess. In 1616 patients with asymptomatic AS in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypertension (n=1340) was associated with a 56% higher rate of ischemic cardiovascular events and a 2-fold \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhigher mortality rate (both P<0.01) than those seen in normotensive patients with AS, although no impact on \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmortality was observed.\\n\\n2. Concurrent CAD is common in patients with AS, and all patients should be screened\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mand treated for hypercholesterolemia, with GDMT used for primary and secondary prevention of CAD. In RCTs of \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin therapy for mild to moderate AS, although aortic valve event rates...\\n# e300 Grundy et al.\\n\\n# J A C C\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mV O L . 7 3 , N O . 2 4 , 2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m: e 2 8 5 - 3 5 0\\n\\nLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto a lipid specialist may be indicated.\\n\\n# Recommendation-Specific Supportive Text\\n\\n1. Patients with \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mprimary severe hypercholesterolemia (LDL-C levels \\u2265190 mg/dL [\\u22654.9 mmol/L]) have a high-risk of ASCVD\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have been no \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrandomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\u2265190 mg/dL (\\u22654.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbaseline LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdeath in those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof 2,560 exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlong-term follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtherapy reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mphenotypic or genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mASCVD risk in both primary- and secondary-prevention trials and because high-intensity statins provide greater \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mASCVD risk reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mshould be administered to patients with primary severe hypercholesterolemia.\\n2. A large placebo-controlled RCT\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mexamined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 mg daily, on carotid intima-media \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was greater in the combined-therapy group,\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbut there was no difference in carotid intima-media thickness between the 2 groups. The study was not powered \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto examine the risk of ASCVD events (S4.2-10). However, a very large placebo-controlled RCT examining ASCVD \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2moutcomes in post-ACS patients, performed over a period of 7 years, showed that the addition of ezetimibe 10 mg \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto simvastatin 40 mg daily resulted in greater ASCVD risk reduction than that produced by statin monotherapy \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S4.2-8). Secondary-prevention patients with certain ASCVD risk indicators exhibit greater ASCVD risk reduction\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfrom ezetimibe therapy than do patients without these characteristics (S4.2-20). Patients with severe \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia who are adherent to statins, achieve <50% reduction in LDL-C levels with maximally \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtolerated statin therapy, and have an LDL-C level \\u2265100 mg/dL (\\u22652.6 mmol/L) are likely to derive \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madditional ASCVD risk reduction from ezetimibe add-on therapy through additional LDL-C lowering (S4.2-9).\\n3. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mWhen administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins with \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mor without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\\n4. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mPCSK9 inhibitors are promising drugs for treatment of FH\\nprevention of cardiovascular disease: an opportunity \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mto harmonize guidelines. JAMA Cardiol. 2017;2:1175\\u20136.\\n\\nS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLifetime risks of cardiovascular disease. N Engl J Med. 2012; 366:321\\u20139.\\n\\nS4.4.4.2-11. Lehr AL, Driver \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505\\u20136.\\n\\nS4.4.4.2-12. Omura JD, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mWatson KB, Loustalot F, et al. Primary care providers\\u2019 awareness of physical activity-related intensive \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbehavioral counseling services for cardiovascular disease prevention. Am J Health Promot. 2018. \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m890117118784226.\\n\\n# 4.4.4.3. Children and Adolescents\\n\\nS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mal. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children.\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mHeart Vessels. 2009;24:419\\u201324.\\n\\nS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mintervention using Dance Dance Revolution on endothelial function and other risk factors in overweight \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mchildren. Int J Pediatr Obes. 2009;4:205\\u201314.\\n\\nS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. \u001b[0m\u001b[2m                     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2014;8:181\\u20136.\\n\\nS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109\\u201317.\\n\\nS4.4.4.3-5. \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mNiinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mof age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007; \u001b[0m\u001b[2m              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m116:1032\\u201340.\\n\\nS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthe Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256\\u201364.\\n\\nS4.4.4.3-7. Dorgan JF, \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLiu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIntervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. \u001b[0m\u001b[2m                               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2011;96:E1999\\u20132008.\\n\\nS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric \u001b[0m\u001b[2m            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708\\u201313.\\n\\nS4.4.4.3-9. \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mZachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification: \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mbenchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122\\u20133.\\n\\nS4.4.4.3-10. Torvik K, Narverud I,\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mOttestad I, et al. Dietary counseling is associated with an improved lipid profile in children with familial \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhypercholesterolemia. Atherosclerosis. 2016;252:21\\u20137.\\n\\nS4.4.4.3-11. Koletzko B, Kupke I, Wendel U. \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTreatment of hypercholesterolemia in children and adolescents. Acta Paediatr. \u001b[0m\u001b[2m                                 \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m1992;81:682\\u20135.\\n\\nS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnutrition education for hypercholesterolemic children.\\n# Grundy et al.\\n\\n# J A C C V O L . 7 3 , N O . 2 4 , \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2 0 1 9\\n\\n# 2018 Cholesterol Clinical Practice Guideline\\n\\n# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\\n\\n# \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mTable 3 High-, Moderate-, and Low-Intensity Statin Therapy*\\n\\n|High Intensity| | |Moderate Intensity|Low \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIntensity|\\n|---|---|---|---|---|\\n|LDL-C lowering\\u2020|\\u226550%| \u001b[0m\u001b[2m                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m|30%\\u201349%|&lt;30%|\\n|Statins|Atorvastatin (40 mg\\u2021) 80 mg Rosuvastatin 20 mg (40 mg)|Atorvastatin 10 mg\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(20 mg) Rosuvastatin (5 mg) 10 mg Simvastatin 20\\u201340 mg\\u00a7 Pravastatin 40 mg (80 mg) Lovastatin 40 mg \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(80 mg) Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 1\\u20134 mg|Simvastatin 10 mg Pravastatin \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m10\\u201320 mg Lovastatin 20 mg Fluvastatin 20\\u201340 mg| |\\n\\nPercent LDL-C reductions with the primary statin\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedications used in clinical practice (atorvastatin, rosuvastatin, simvastatin) were estimated using the median\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mreduction in LDL-C from the VOYAGER database (S3.2.1-2). Reductions in LDL-C for other statin medications \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(fluvastatin, lovastatin, pitavastatin, pravastatin) were identified according to FDA-approved product labeling\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min adults with hyperlipidemia, primary hypercholesterolemia, and mixed dyslipidemia (S3.2.1-4). Boldface type \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mindicates specific statins and doses that were evaluated in RCTs (S3.2.1-3, S3.2.1-5\\u2014S3.2.1-16), and the \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mCholesterol Treatment Trialists\\u2019 2010 meta-analysis (S3.2.1-17). All these RCTs demonstrated a reduction \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2min major cardiovascular events.\\n\\n*Percent reductions are estimates from data across large populations. \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIndividual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.2.1-2).\\n\\n\\u2020LDL-C lowering that should occur with the dosage listed below each \u001b[0m\u001b[2m                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mintensity.\\n\\n\\u2021Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIDEAL (Incremental Decrease through Aggressive Lipid Lowering) study (S3.2.1-3).\\n\\n\\u00a7Although simvastatin \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mFDA because of the increased risk of myopathy, including rhabdomyolysis.\\n\\nBID indicates twice daily; FDA, \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mU.S. Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mtrial; VOYAGER, an individual patient data meta-analysis of statin therapy in at-risk groups: effects of \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrosuvastatin, atorvastatin, and simvastatin; and XL, extended release.\\n\\n# 3.1.2. Lifestyle Therapies and \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mMetabolic Syndrome\\n\\nLifestyle therapies are particularly indicated for the metabolic syndrome, which is a \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcluster of risk factors associated with an increased risk of ASCVD, diabetes mellitus, and all-cause death \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(S3.1.2-1, S3.1.2-2). Metabolic syndrome is a risk-enhancing factor for ASCVD. The most widely used clinical \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdefinition of metabolic syndrome is that proposed by an international consortium of cardiovascular and diabetes\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2morganizations (S3.1.2-3). The diagnosis is made by the presence of any 3 of the following 5 risk factors: \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated waist circumference, elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2melevated fasting glucose (Table S2 in the Web Supplement). Metabolic syndrome is closely linked to excess \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mweight and particularly to abdominal obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrisen sharply among both adults and children as levels of overweight and obesity have risen. Metabolic\"\u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  },\u001b[0m\u001b[2m                                                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  {\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"role\": \"tool\",\u001b[0m\u001b[2m                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"tool_call_id\": \"call_Wj83hyOr277uKGy1oSceoOi9\",\u001b[0m\u001b[2m                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"name\": \"search_bing_grounding\",\u001b[0m\u001b[2m                                                                           \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m    \"content\": \"In February 2025, the FDA accepted the Biologics License Application for Lerodalcibep, a novel \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mthird-generation PCSK9 inhibitor developed by LIB Therapeutics. This drug aims to reduce low-density \u001b[0m\u001b[2m          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease (ASCVD) and primary \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia. Lerodalcibep is designed to be a more convenient, once-monthly, subcutaneous injection that \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdoes not require refrigeration. The FDA's action date for the review is set for December 12, \u001b[0m\u001b[2m                  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2025\\u30100\\u2020source\\u3011\\u30101\\u2020source\\u3011.\"\u001b[0m\u001b[2m                                                       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m  }\u001b[0m\u001b[2m                                                                                                            \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m]\u001b[0m\u001b[2m                                                                                                              \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Raw response message:                                                                                           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessage(content=\"### Patient Summary\\n- **Name:** Gloria Paul\\n- **Date of Birth:** July 15, 1944 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (Age: 79)\\n- **Gender:** Other\\n- **Medical Condition:** Hyperlipidemia\\n- **Medications:** Atorvastatin\\n-     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Allergies:** None\\n- **Blood Type:** O+\\n- **Last Visit Date:** March 26, 2024\\n- **Smoking Status:** Never   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Smoker\\n- **Alcohol Consumption:** Light drinker (1-2 times a week)\\n- **Exercise Frequency:** Light\\n-         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Occupation:** Administrator, sports\\n- **Height:** 176.2 cm\\n- **Weight:** 77.7 kg\\n- **Blood Pressure:**     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 120/79 mmHg\\n- **Heart Rate:** 90 bpm\\n- **Notes:** Descriptions of personal insights and lifestyle changes are │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ noted.\\n\\n### ACC Guidelines for Hyperlipidemia\\n1. **Statin Therapy:**\\n   - **Class I**: Treatment with       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statin medication is recommended for patients with significant atherosclerotic diseases to reduce LDL           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol levels below 100 mg/dL.\\n   - **Class IIa**: It is reasonable to aim for LDL cholesterol levels     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ near or below 70 mg/dL in patients who have had ischemic stroke.\\n   - If LDL targets are not achieved with     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ statins, intensifying therapy with additional medications may be appropriate.\\n\\n2. **Lifestyle                 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Modifications**: Intensifying lifestyle changes, including diet and exercise, is essential for managing         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ hyperlipidemia.\\n\\n3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ frequently co-occur with hyperlipidemia, which complicates clinical management.\\n\\n### New Medication Updates   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ (As of February 2025)\\n- The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9 │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ inhibitor designed for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \\n- **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ making it a potentially more convenient treatment option.\\n- The FDA's review action date for this medication   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ is December 12, 2025.\\n\\n### Summary\\nGloria Paul is a 79-year-old woman effectively managed on atorvastatin    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for hyperlipidemia, meeting current ACC guidelines emphasizing the use of statins to achieve lower LDL          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ cholesterol targets while recommending lifestyle modifications. Notably, the recent approval process for a new  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ drug, Lerodalcibep, may offer further treatment options for patients with similar conditions. Always ensure     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ adherence to guidelines when managing complex medical cases, especially in elderly patients.\", refusal=None,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ role='assistant', audio=None, function_call=None, tool_calls=None)                                              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mRaw response message:\u001b[0m\u001b[2m                                                                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessage(content=\"### Patient Summary\\n- **Name:** Gloria Paul\\n- **Date of Birth:** July 15, 1944\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(Age: 79)\\n- **Gender:** Other\\n- **Medical Condition:** Hyperlipidemia\\n- **Medications:** Atorvastatin\\n- \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Allergies:** None\\n- **Blood Type:** O+\\n- **Last Visit Date:** March 26, 2024\\n- **Smoking Status:** Never \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mSmoker\\n- **Alcohol Consumption:** Light drinker (1-2 times a week)\\n- **Exercise Frequency:** Light\\n- \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Occupation:** Administrator, sports\\n- **Height:** 176.2 cm\\n- **Weight:** 77.7 kg\\n- **Blood Pressure:** \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m120/79 mmHg\\n- **Heart Rate:** 90 bpm\\n- **Notes:** Descriptions of personal insights and lifestyle changes are\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnoted.\\n\\n### ACC Guidelines for Hyperlipidemia\\n1. **Statin Therapy:**\\n   - **Class I**: Treatment with \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatin medication is recommended for patients with significant atherosclerotic diseases to reduce LDL \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol levels below 100 mg/dL.\\n   - **Class IIa**: It is reasonable to aim for LDL cholesterol levels \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnear or below 70 mg/dL in patients who have had ischemic stroke.\\n   - If LDL targets are not achieved with \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mstatins, intensifying therapy with additional medications may be appropriate.\\n\\n2. **Lifestyle \u001b[0m\u001b[2m               \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mModifications**: Intensifying lifestyle changes, including diet and exercise, is essential for managing \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mhyperlipidemia.\\n\\n3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfrequently co-occur with hyperlipidemia, which complicates clinical management.\\n\\n### New Medication Updates \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m(As of February 2025)\\n- The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2minhibitor designed for patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia.\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\\n- **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmaking it a potentially more convenient treatment option.\\n- The FDA's review action date for this medication \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mis December 12, 2025.\\n\\n### Summary\\nGloria Paul is a 79-year-old woman effectively managed on atorvastatin \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor hyperlipidemia, meeting current ACC guidelines emphasizing the use of statins to achieve lower LDL \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcholesterol targets while recommending lifestyle modifications. Notably, the recent approval process for a new \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mdrug, Lerodalcibep, may offer further treatment options for patients with similar conditions. Always ensure \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2madherence to guidelines when managing complex medical cases, especially in elderly patients.\", refusal=None, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mrole='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m                                             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Patient Summary                                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Name:** Gloria Paul                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Date of Birth:** July 15, 1944 (Age: 79)                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Gender:** Other                                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medical Condition:** Hyperlipidemia                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medications:** Atorvastatin                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Allergies:** None                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Type:** O+                                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Last Visit Date:** March 26, 2024                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Smoking Status:** Never Smoker                                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Alcohol Consumption:** Light drinker (1-2 times a week)                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Exercise Frequency:** Light                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Occupation:** Administrator, sports                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Height:** 176.2 cm                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Weight:** 77.7 kg                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Pressure:** 120/79 mmHg                                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Heart Rate:** 90 bpm                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Notes:** Descriptions of personal insights and lifestyle changes are noted.                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### ACC Guidelines for Hyperlipidemia                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Statin Therapy:**                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Class I**: Treatment with statin medication is recommended for patients with significant atherosclerotic </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> diseases to reduce LDL cholesterol levels below 100 mg/dL.                                                      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - **Class IIa**: It is reasonable to aim for LDL cholesterol levels near or below 70 mg/dL in patients who   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> have had ischemic stroke.                                                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - If LDL targets are not achieved with statins, intensifying therapy with additional medications may be      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> appropriate.                                                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Lifestyle Modifications**: Intensifying lifestyle changes, including diet and exercise, is essential for   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> managing hyperlipidemia.                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they frequently         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> co-occur with hyperlipidemia, which complicates clinical management.                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### New Medication Updates (As of February 2025)                                                                </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9 inhibitor designed for </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> patients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia.                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration,      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> making it a potentially more convenient treatment option.                                                       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - The FDA's review action date for this medication is December 12, 2025.                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Summary                                                                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Gloria Paul is a 79-year-old woman effectively managed on atorvastatin for hyperlipidemia, meeting current ACC  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> guidelines emphasizing the use of statins to achieve lower LDL cholesterol targets while recommending lifestyle </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> modifications. Notably, the recent approval process for a new drug, Lerodalcibep, may offer further treatment   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> options for patients with similar conditions. Always ensure adherence to guidelines when managing complex       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> medical cases, especially in elderly patients.                                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Patient Summary\u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Name:** Gloria Paul\u001b[0m\u001b[1;32m                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Date of Birth:** July 15, 1944 (Age: 79)\u001b[0m\u001b[1;32m                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Gender:** Other\u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medical Condition:** Hyperlipidemia\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medications:** Atorvastatin\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Allergies:** None\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Type:** O+\u001b[0m\u001b[1;32m                                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Last Visit Date:** March 26, 2024\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Smoking Status:** Never Smoker\u001b[0m\u001b[1;32m                                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Alcohol Consumption:** Light drinker (1-2 times a week)\u001b[0m\u001b[1;32m                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Exercise Frequency:** Light\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Occupation:** Administrator, sports\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Height:** 176.2 cm\u001b[0m\u001b[1;32m                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Weight:** 77.7 kg\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Pressure:** 120/79 mmHg\u001b[0m\u001b[1;32m                                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Heart Rate:** 90 bpm\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Notes:** Descriptions of personal insights and lifestyle changes are noted.\u001b[0m\u001b[1;32m                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### ACC Guidelines for Hyperlipidemia\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Statin Therapy:**\u001b[0m\u001b[1;32m                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Class I**: Treatment with statin medication is recommended for patients with significant atherosclerotic\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mdiseases to reduce LDL cholesterol levels below 100 mg/dL.\u001b[0m\u001b[1;32m                                                     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - **Class IIa**: It is reasonable to aim for LDL cholesterol levels near or below 70 mg/dL in patients who \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mhave had ischemic stroke.\u001b[0m\u001b[1;32m                                                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - If LDL targets are not achieved with statins, intensifying therapy with additional medications may be \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mappropriate.\u001b[0m\u001b[1;32m                                                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Lifestyle Modifications**: Intensifying lifestyle changes, including diet and exercise, is essential for \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmanaging hyperlipidemia.\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m3. **Comorbidities**: Special attention should be given to hypertension and diabetes as they frequently \u001b[0m\u001b[1;32m       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mco-occur with hyperlipidemia, which complicates clinical management.\u001b[0m\u001b[1;32m                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### New Medication Updates (As of February 2025)\u001b[0m\u001b[1;32m                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- The **FDA accepted the Biologics License Application for Lerodalcibep**, a novel PCSK9 inhibitor designed for\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mpatients with atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. \u001b[0m\u001b[1;32m                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Features**: Lerodalcibep is a once-monthly subcutaneous injection that does not require refrigeration, \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmaking it a potentially more convenient treatment option.\u001b[0m\u001b[1;32m                                                      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- The FDA's review action date for this medication is December 12, 2025.\u001b[0m\u001b[1;32m                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Summary\u001b[0m\u001b[1;32m                                                                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mGloria Paul is a 79-year-old woman effectively managed on atorvastatin for hyperlipidemia, meeting current ACC \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mguidelines emphasizing the use of statins to achieve lower LDL cholesterol targets while recommending lifestyle\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmodifications. Notably, the recent approval process for a new drug, Lerodalcibep, may offer further treatment \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32moptions for patients with similar conditions. Always ensure adherence to guidelines when managing complex \u001b[0m\u001b[1;32m     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mmedical cases, especially in elderly patients.\u001b[0m\u001b[1;32m                                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "run_multi_step_agent(\"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "agentic-rag-venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
